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Abstract 
Heart failure (HF) is a major public health burden, with over 6.5 million adults in 
the US suffering from the disease.  Moderate to advanced-stage heart failure patients 
implanted with cardiac resynchronization therapy (CRT) devices suffer from increased 
mortality risk and frequent inpatient hospitalization.  Efforts to reduce mortality and 
prevent HF-related hospitalizations in this population would be of significant benefit to 
the patients, as well as to the health care system.  In this doctoral dissertation, we present 
three manuscripts examining associations between CRT device-measured and device-
programmed parameters and patient mortality and HF-hospitalization. 
 In the first manuscript, we examined the device-measured parameter of 
intrathoracic impedance, and whether an OptiVol® threshold crossing or time above 
OptiVol® threshold were associated with patient mortality and HF-related 
hospitalization.  We found that patients with >15.1% of their follow-time above threshold 
had a 4.2 times greater risk of mortality and a 3.2 times greater risk of HF-hospitalization 
than those patients with <4.1% of follow-up time above threshold.  In addition, a single 
OptiVol® crossing was associated with an 87% higher mortality rate, and a 70% higher 
HF-hospitalization rate. 
 In the second manuscript, we examined the device-measured associations between 
biventricular pacing percentage, AF burden, and heart rate variability on patient mortality 
and HF-related hospitalization.  We found a complex relationship between biventricular 
pacing percentage, AF, AVN ablation, and HRV where patients with <99% bi-V pacing 
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percentage had an increased rate of mortality and hospitalization among those with no 
baseline device-measured atrial fibrillation.  In addition, AVN ablation was associated 
with worse outcomes among those with high baseline HRV, suggesting that the potential 
loss of benefits of higher HRV must be weighed when performing an AVN ablation 
procedure. 
 The third manuscript looked at parameters associated with an increased risk of 30-
day HF-related rehospitalization. We found that parameters associated with kidney 
function to be of critical importance in evaluating the risk of patients at higher risk of 
rehospitalization within 30 days.  Patients with a daily intrathoracic impedance 
measurement >8Ω less than the reference impedance value on the day of discharge, a 
diagnosis of chronic kidney disease, no diuretic prescription, male sex, longer duration of 
heart failure at the time of index hospitalization, and those with a prior CABG procedure 
to have a higher risk of 30-day rehospitalization.  Model AUC, NRI, IDI, and Hosmer-
Lemeshow statistics indicated good model discrimination with respect to a previously 
published model with good calibration.
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1 Introduction	to	Heart	Failure	
Heart failure (HF) remains one of the most prevalent and costly cardiovascular 
diseases to treat in the health care system.  Data from the National Health and Nutrition 
Examination Survey (NHANES) gathered 
between 2011 and 2014 show that 
approximately 6.5 million adults in the US 
have heart failure.1  Another study projected 
that the prevalence of heart failure among the 
US population would increase from 2.4% in 
2012 to 3.0% in 2030, representing a 23% 
increase over 2012 levels.  Accounting for the 
projected growth of the US population over 
this time period, this represents a 46% 
increase in the absolute number of Americans 
living with heart failure by 2030.2  This 
projected increase would also come with a 
corresponding 254% increase in direct medical 
costs associated with treating and managing 
the disease, and a further 70% increase in 
“indirect”, or lost productivity costs associated with HF.  These costs stand at $20.9 
billion and $9.8 billion, respectively, as of 2012. 2  Currently known risk factors for the 
Figure 1. – Risk Factors and Markers for Heart 
Failure.   
Adapted from Kenchaiah S, Narula J, Vasan RS. Med 
Clin N Am. 2004;88:1145-1172. 
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development of heart failure are listed in Figure 1, and include coronary heart disease 
(CHD), hypertension, increasing age, male sex, diabetes, valvular disease, and obesity.3  
However, the two factors of CHD and hypertension alone are believed to account for 
fully three-fourths of all heart failure cases, although interaction with other factors such 
as race, sex, and age may exacerbate or ameliorate the effects of CHD or hypertension, or 
both. 4,5  With respect to CHD, it has been proposed that increased survival from 
myocardial infarction in recent decades have led to a corresponding increase in HF 
prevalence.6,7   
1.1 Pathophysiology of Heart Failure 
Heart failure itself is a complex, multifaceted disease, and has been broadly defined 
as a condition where the heart is rendered incapable of ejecting blood supplied to it by the 
venous system.8  An important concept to understand in heart failure is that of cardiac 
output.  Cardiac output is combination of both stroke volume (the amount of blood 
pumped by the left ventricle in a single contraction) as well as heart rate (the number of 
contractions per minute). Heart failure, importantly, does therefore not include diseases 
where insufficient blood is supplied to the heart due to blood loss or other impairment of 
blood return.  Heart failure is dichotomized into two main types: heart failure with 
reduced ejection fraction (or HRrEF, formerly known as systolic heart failure) and heart 
failure with preserved ejection fraction (or HFpEF, formerly known as diastolic heart 
failure), both of which affect the left ventricle.  HFrEF and HFpEF are both estimated to 
be equally prevalent at around 50% of heart failure cases, but the dividing line between 
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the two is of some debate.9  In general, HFrEF is defined by the American College of 
Cardiology (ACC) and American Heart Association (AHA) guidelines  as a clinical 
diagnosis of heart failure with a measured ejection fraction <40%.10  Other definitions 
may set this distinction at <35% or ≤40%.  Similarly, HFpEF is defined as a clinical 
diagnosis of heart failure with an ejection fraction ≥50%.  Patients with ejection fractions 
in the range of 40% to 50% are therefore technically “in-between” the two categories, but 
are often treated similarly to those with HFrEF.10  The most common causes of both 
HFrEF and HFpEF are hypertension, valvular disease, direct insult due to myocardial 
infarction (typically associated with HFrEF, specifically), or to ischemic heart disease 
more generally. HFpEF is generally more difficult to clinically diagnose as there is no 
evident reduction in ejection fraction in the presence of heart failure symptoms, but still 
may have clinically relevant LV dysfunction upon evaluation with cardiac catheterization 
or echocardiography.11   Valvular disease, in particular mitral valve stenosis, causes heart 
failure through progressive inability for the left ventricle to fill with blood due to mitral 
valve dysfunction, increasing backpressure into the pulmonary vein and resulting 
pulmonary congestion.   
A decrease in cardiac output due to any of the above-listed reasons results in 
activation of two major adaptive responses in the heart:  a neurohormonal autonomic 
response, shown conceptually in Figure 2, and in molecular and morphological changes 
to the heart.  Inability to maintain cardiac output activates the sympathetic nervous 
system (SNS) with a corresponding decrease in parasympathetic activity.  This 
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sympathetic activity stimulates physiological changes that increase cardiac output either 
directly by increasing the heart rate, or indirectly by increasing muscle contractility that, 
in turn, increases the amount of blood pumped from the heart per beat (increased stroke 
volume).   The blood vessels also contract with an increase in SNS activity, which then 
cause an increase in blood pressure.  All of these changes result in a net increase in the 
cardiac workload, which in turn 
causes yet more left-ventricular 
remodeling and dysfunction in the 
form of molecular and 
morphological changes such as 
hypertrophy and dilatation.8  The 
cycle then repeats, resulting in a 
progressive deterioration of 
cardiac function and its ability to 
pump blood. 
1.2 Classification of Heart Failure 
In order to describe and partially quantify the progressive nature of heart failure, 
two main systems have been established to classify heart failure patients:  the New York 
Heart Association (NYHA) classification scheme, and the American College of 
Cardiology/ American Heart Association (ACC/AHA) classification guidelines.  The 
 
↑LV Dysfunction 
(Decreased Cardiac 
Output) 
↑Mean Arterial 
Pressure 
↑Cardiac Workload 
↑Heart Rate Vasoconstriction ↑Contractility 
↑Stroke Volume ↑Cardiac Output 
Vagal Nerve 
Stimulation 
↑Sympathetic Nervous 
System Activation 
Figure 2. – Theoretical Model of Autonomic Response to Heart 
Failure 
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NYHA classification refers primarily to the day-to-day functional capacity of the patient, 
and is shown in  
Table 1. 
 
Class Description 
I No limitation is experienced in any 
activities; there are no symptoms from 
ordinary activities. 
II Slight, mild limitation of activity; the 
patient is comfortable at rest or with mild 
exertion. 
III Marked limitation of any activity; the 
patient is comfortable only at rest. 
IV Any physical activity brings on discomfort 
and symptoms occur at rest. 
 
Table 1. – NYHA Classification Scheme 
 
Alternately, the ACC/AHA guidelines shown in Table 2, which were developed in 2001 
added a “pre-failure” category identifying people at high risk for the disease, but without 
either clinical or sub-clinical symptoms. 
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Stage Description 
A Patients at high risk for developing HF in 
the future but no functional or structural 
heart disorder. 
B Structural heart disorder but no symptoms at 
any stage. 
C Previous or current symptoms of heart 
failure in the context of an underlying 
structural heart problem, but managed with 
medical treatment. 
D Advanced disease requiring hospital-based 
support, heart transplant or palliative care. 
 
Table 2. – ACC/AHA Classification Guidelines 
 
These measures are subjective, but the classifications (or changes in class over time 
within patients) are often used as predictors in some studies, and as outcomes in others.  
It is interesting to note that in the ACC/AHA classification scheme that even those who 
are not actually diagnosed with heart failure, but are merely at risk of developing heart 
failure are considered to be in Stage A heart failure.  Further, it could be construed that 
after a myocardial infarction of any type or severity, that a patient would be considered in 
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Stage B heart failure, even though there may be no actual functional physiological 
impairment. 
1.3 Treatments for Heart Failure 
Overall, there are three main strategies in treating heart failure.  First, 
pharmaceutical and lifestyle-change strategies are usually the initial approach taken in 
managing the disease.  Lifestyle changes include dietary modifications, quitting smoking, 
and exercising.  Often, though, if lifestyle adaptations have not been adopted at very early 
stages of the disease they are of very modest effectiveness in treating existing disease 
alone.  Pharmaceutical options at this stage help manage risk factors, such as treating a 
patient’s hypertension, diabetes, or dyslipidemia.  In patients that remain or become 
refractory to medical treatment as the disease progresses, the second option is that of 
medical device implantation such as cardiac resynchronization therapy (CRT) or, in later 
stages of the disease, a ventricular assist device (VAD).  The third and most drastic 
treatment for heart failure is that of heart transplantation.10 
1.3.1 Medications	
There are many pharmaceutical options for treating heart failure.  In fact, the median 
number of unique medications a heart failure patient takes for treating HF and other co-
morbid conditions is approximately 11, with an interquartile range from 8 to 17 
medications.12  Many of these medications target a specific strategy for addressing the 
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various autonomic response pathways described in Figure 2.  Specifically, the various 
treatments for treating heart failure fall into the following categories: 
1. Vasodilation.  These medications attempt to intervene upon vasoconstriction 
associated with sympathetic nervous system activation. These include 
angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor 
blockers (ARBs), isosorbide dinitrate, and hydralazine hydrochloride.  Their 
mechanism of action is either to prevent angiotensin II or aldosterone from being 
formed, or to block activation of angiotensin II receptors located on smooth 
muscle cells.8,13  Both angiotensin II and aldosterone are key components of the 
renin-angiotensin system, which regulates the body’s arterial blood pressure.  A 
recently approved drug therapy combines an ARB (valsartan) with a neprilysin 
inhibitor (sacubitril).  Inhibition of neprilysin increases levels of several 
vasodilating peptides, such as bradykinin and adrenomedullin.14 
2. Heart rate control.  Sympathetic nervous system activation also results in an 
increased heart rate through the release of epinephrine and norepinephrine. These 
compounds bind with β-I adrenergic receptor sites selectively found on cardiac 
muscle tissue which, in turn, affects heart rate and muscle contractility.  Beta-
blocker medications compete with epinephrine and norepinephrine for adsorption 
on these receptor sites, thereby preventing activation, and serving to lower heart 
rate, reduce contractility, decrease relaxation rate, increase cardiac output, inhibit 
release of renin, and reduce blood pressure.13  Other medications for heart rate 
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control include positive inotropes such as digoxin.  Digoxin inhibits sodium-
potassium ATP-ase.  Inhibiting the function of this enzyme results in a change to 
the cardiac action potential cycle, and a corresponding increase in intracellular 
calcium.  This elevated calcium then results in a negative chronotropic effect, 
lowering the heart rate.13 
3. SNS activity reduction.  Beta-blocker medications also treat heart failure through 
another mechanism by reducing sympathetic nervous system activation in general.  
The reduction in renin production via beta-blocker uptake leads to reduced 
aldosterone via the renin-angiotensin-aldosterone system, which in turn, leads to 
less epinephrine and norepinephrine production and reduced SNS activity.8,13 
4. Reduce cardiac workload.  Diuretics work through two separate mechanisms.  
First, they work by reducing volume of extracellular fluid via urinary excretion of 
sodium and water, thereby preventing or reducing edema found in episodes of 
acute HF decompensation.  Further, thiazide-type diuretics provide blood pressure 
control, decreasing the mean arterial pressure and therefore decreasing cardiac 
workload.13  Aldosterone antagonists, such as spironolactone, are another class of 
drugs which work via a similar mechanism to diuretics.  The main effect of 
aldosterone in the body is to retain sodium and water, resulting in increased 
intravascular fluid volume.  Aldosterone antagonists function as competitors for 
sites of aldosterone-dependent intracellular sodium channels, thereby increasing 
excretion of sodium and water which would otherwise be blocked by aldosterone. 
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Overall, there are many options for pharmacological treatment available to 
physicians for the management of heart failure.  However, adverse effects from these 
medications need to be carefully monitored and are relatively common, especially 
considering the sheer number of medications prescribed to the typical heart failure 
patient.  Further, in prescribing a medical regimen for a heart failure patient, the 
physician must take considerable effort to examine possible interactions between the 
various medications for each patient and any other potential medications that patient is 
taking for comorbid conditions. 
Management of prescribed medication is also an issue.  Many patients have 
difficulty adhering to their scheduled regimen of prescriptions, which can also have 
adverse consequences on the patient’s outcome.  For example, missing a diuretic 
prescription for a few days in combination with failure to eat a low-salt diet may be 
enough to trigger an acute decompensation event, and a trip to the emergency room.   
The cost of heart failure medications can also be a significant burden to the patient, with 
an estimated annual out-of-pocket expense on heart failure drugs alone estimated at 
between $750 and $1,626 per person per year.15   
1.3.2 Medical	Devices	
If optimal medical therapy proves insufficient in managing a patient’s symptoms, 
other therapies, such as an implanted medical device may also be considered.  Such 
devices meter electrical impulses to either the ventricles or the atria of the heart, or both 
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in an attempt to correct the mechanical pumping dysfunction of a failing heart by “re-
timing” the heart’s electrical signals.  These impulses are administered by the device in 
such a way to mimic the natural rhythm of the heart as closely as possible.  In heart 
failure, these devices typically provide electrical stimulation therapy to the left and right 
ventricles separately, as well as the right atrium, and are called cardiac resynchronization 
therapy (CRT) devices.  When a device paces both the right and left ventricles, it is 
referred to as “bi-ventricular” pacing.  The devices themselves are implanted pectorally 
under the skin, just inferior to the clavicle.  Electrical stimulation is delivered by the 
device through three insulated, flexible electrical wires, or “leads”, to each of the three 
chambers directly, as shown below in Figure 3.  
   12 
 
 
Figure 3. – Cardiac Resynchronization Therapy with Defibrillator (CRT-D) Device and Lead Placement 
 
 The leads are each inserted surgically using a catheter, affixed in place, and 
tested for efficacy.  The catheter is then withdrawn, leaving the lead in place. Each lead 
may provide electrical stimulation separately, and the timing between atrial and 
ventricular stimulation is often optimized via echocardiography to provide maximal 
systolic blood flow and diastolic filling volume.  Left and right ventricle timing is also 
programmable, but is only rarely changed from the nominal, simultaneous stimulation 
setting.  
Left ventricular lead 
Right ventricular lead 
Right atrial lead 
Implanted CRT-D 
Device 
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While cardiac resynchronization therapy has been demonstrated to be an effective 
therapy for treating heart failure patients, there remains the problem that some patients 
receive no apparent benefit from the device in that their condition either shows no 
improvement, or continues to worsen. Such “nonresponder” rates can range from 25% to 
as high as 50% of clinical cohorts.16-19  However, as CRT implantation carries both 
patient risks and costs, it is desirable that this therapy be as effective as possible.  As 
mentioned above, if an implanted device fails to improve a patient’s condition, there are 
few options left for treatment, and the costs associated with the device and the associated 
surgery to implant and potentially explant the device may have been wasted.  Since 
anatomy and physiology differ from patient to patient, it is likely that no single 
combination of programmed CRT device settings is optimal for all CRT patients.  Rather, 
device programming must be individualized for each patient. 
One programmable parameter of these devices which does not treat heart failure 
directly, but rather can be used as a patient and/or clinician management tool is that of 
intrathoracic impedance, as it is inversely correlated with left ventricular filling 
pressure.20  The devices measure impedance between the tip of the lead in the right 
ventricular apex and the device itself, implanted just inferior to the clavicle, by sending a 
known pulse of current through the electrode, and measuring the change in voltage 
between the lead tip and the metal case of the device.  The impedance is then calculated 
via Ohm’s law.  The device stores these impedance measurements and accumulates 
changes in those measurements from a calculated reference value.  If this accumulated 
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impedance measurement, called the OptiVol® fluid index value, drops below the 
reference value for an extended period of time, indicating that fluid is building up in the 
lungs, the device can alert the clinician via a home-monitoring network.  
 
Figure 4. – Example of Patient Intrathoracic Impedance Trends and OptiVol® Threshold Crossing. 
 
In Figure 4, an example patient’s impedance measurements began to trend below 
the reference impedance value in mid-June 2008, resulting in the OptiVol® fluid index 
value to accumulate over several weeks in June, July and August, with an actual fluid 
index threshold crossing occurring in early July, and ultimately a hospitalization event 
occurring in August. Yu, et al. showed that such a threshold crossing was 76.9% sensitive 
From Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu C-M, Cowie MR. Eur. 
Heart J. 2011; 32(18):2266-2273. 
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in predicting hospitalization for fluid overload, with an incidence of 1.5 false positives 
per patient-year when the nominal programmed threshold value of 60 Ω-days was used.20  
Small, et al., reported that those who had at least three or more 60 Ω-day threshold 
crossings during an initial 4 month evaluation period after CRT device implant had a 
significantly higher risk of heart failure hospitalization than those with no threshold 
crossings (0.76 hospitalizations per year and 0.14 hospitalizations per year, respectively 
[p-value=0.02]).21  Ypenburg, et al., reported quite different results for the nominal 60 Ω-
day threshold case with nearly 100% sensitivity in predicting a heart failure 
decompensation event, but with near 0% specificity.  After performing a receiver 
operating characteristic (ROC) analysis they proposed an “optimal” threshold value of 
120 Ω -days which offered a sensitivity of 60% and a specificity of 73%.22  These trials, 
upon which regulatory approval was based, were very small in nature (33 and 115 
patients, respectively) and possibly suffered from the fact that they may not represent 
typical clinical usage or device management when working with heart failure patients.  
More recently, Soga, et al., performed a similar ROC analysis on a similarly-sized cohort 
(n=123), and proposed an optimum threshold value of 114 Ω-days, optimizing the 
sensitivity at 89.5% and the specificity at 73.0%, with an AUC of 87.1%.23  They further 
found that for the default 60 Ω-day programmed threshold setting, the sensitivity and 
specificity dropped to 83.8% and 28.4%, respectively.  Conraads, et al., likewise found 
very low sensitivity for OptiVol® threshold crossings, but also observed that sensitivity  
   16 
 
increased over time from 5.3% during the first 34-63 days to 42.1% for those 
patients with crossings after 148 days after implant.24 
A previous study used Medtronic device data along with the Social Security Death 
Index (SSDI) to look at whether an Optivol® threshold crossing during the initial 6 
months after CRT device implantation was predictive of subsequent patient mortality in a 
large cohort of 21,217 patients.25  It was found that among those who had an Optivol® 
threshold crossing during the initial 6 months after CRT device implantation there was a 
2.15-fold increased risk of death compared to those who did not have a threshold crossing 
for both CRT-D and ICD devices (HR 2.15, 95% CI: 1.95-2.38) over the 36 month 
follow-up period.  Further, this association remained significant among only CRT-D 
devices (HR 2.23, 95% CI: 1.97-2.52), patients which had not experienced a defibrillator 
shock (HR 2.10, 95% CI: 1.90-2.34), and those without device-detected AF (HR 2.09, 
95% CI: 1.86-2.34).  This previous study, however, suffers from the fact that no patient 
covariate information was available other than age and gender to adjust for potential 
differences between the exposure groups, and as such, the results could have been 
significantly biased due to confounding.  Further, OptiVol® crossings which occurred 
after the 6-month time window are ignored, which may also have biased their results. 
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A clinician can examine the OptiVol® data and contact the patient if deemed 
necessary to determine if the patient has become symptomatic, or has experienced a 
worsening of heart failure related symptoms and intervene if necessary.  The goal is to 
prevent the symptoms from becoming so severe that they require hospitalization.  The 
threshold at which this alert is triggered is programmed by the clinician and can be set to 
various values.  If the value is set very low, the 
sensitivity to a true worsening of symptoms will 
be high, but will likely have a low specificity.  
Likewise, if the value is set very high, the 
sensitivity will likely be poor, but the specificity 
will be high.  As shown in Figure 5, intrathoracic 
impedance monitoring will lead to more frequent 
clinician interaction, if the impedance 
monitoring causes the clinician to follow up with 
the patient in the case of a programmed threshold crossing.  This interaction can come in 
the form of calling the patient to schedule an appointment, or may just be handled over 
the phone.  Such increased clinician interaction may lead to better patient adherence to 
medications such as diuretics, which directly affect fluid retention.  There are several 
studies which have indicated that heart failure patient adherence to medication is a 
considerable issue in the management of such patients.26-28  Increased adherence to 
medications and/or increased clinician interaction is expected to lead to a decrease in 
Figure 5. – Theoretical Model of 
Intrathoracic Impedance Monitoring 
Intervention 
Medication adherence  
Out of hospital physician 
interaction 
Intrathoracic impedance 
monitoring 
Hospitalization 
Quality of Life 
Mortality 
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hospitalization due to heart failure-related symptoms, an increase in quality of life, and a 
decrease in patient mortality.29 
Lastly, if the electrical intervention of CRT therapy does not provide 
improvement of a patient’s symptoms, a mechanical solution may be considered.  These 
implanted devices are typically mechanical pumps, and are called ventricular assist 
devices (VADs).  There are several types of VADs, left-ventricular assist devices 
(LVADs), right-ventricular assist devices (RVADs), and bi-ventricular assist devices (bi-
VADs).  They can be of a continuous flow-type, or a pulsatile-type.  The pulsatile-type 
device is meant to mimic the natural, pulsating flow provided by the intrinsic sinus 
rhythm of the heart.  VAD devices have historically been considered as a “bridge to 
transplantation” in order to keep a patient alive until a suitable donor heart can be found.  
More recently, however, VADs have been implanted as “destination therapy”.  In this 
case, the device is meant to be permanently implanted throughout the patient’s remaining 
life. 
1.3.3 Telemonitoring/Remote	Follow-up	
Historically, implanted pacemaker and defibrillator-type devices have required in-
office follow-up visits to record patient data, and more recently to download device-
recorded data from the device.  This was typically done via very short range telemetry.  A 
device programming wand, similar in size and shape to a computer mouse was placed 
over the device, and the device would wirelessly transmit information through the skin to 
the recording head.  More recently, the distance at which the device can transmit 
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information while in the physician’s office has been extended, obviating the need for 
close patient contact with the programming wand. 
Rather than have the patient come into a clinic, another option to conduct patient 
follow-up is through remote patient monitoring.  A patient who receives an implanted 
Medtronic device in the United States is often eligible to participate in an Internet-based 
remote monitoring service for patients.  The CareLink® network was established in 2002 
as a de-identified database containing longitudinal device-programmed and device-
measured information on Implantable Cardiac Monitor (ICM), Implantable Pulse 
Generator (IPG), Implantable Cardioverter-Defibrillator (ICD), and Cardiac 
Resynchronization Therapy with Defibrillator (CRT-D) devices manufactured by 
Medtronic in the United States and is still ongoing.   A patient is sent home with 
equipment to interrogate their implanted device while at home or while traveling, and 
transmit that information to a secure location.  The patient’s clinician can then log in and 
pull up a full record of device information as needed, perhaps eliminating the need for 
some in-office follow-up visits.30  Both the PREFER study, which compared an older, 
more primitive version of such a remote monitoring strategy called transtelephonic 
monitoring (TTM) to the CareLink® network, as well as the CONNECT study showed a 
significant increase in the number of clinically-actionable events identified with 
CareLink®, a decrease in the mean time to first diagnosis of such an event, and in the case 
of the CONNECT study, a reduction in the mean length of a cardiovascular disease-
related hospital stay.31,32  Boriani, et al. recently published the phase 1 results of their 
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MORE-CARE study, which demonstrated that the time from a device-detected event, 
such as impedance-threshold crossing, until a clinical decision was made was reduced to 
2 days (IQR: 1 to 4 days) among the remote monitored group, compared to 29 days (IQR: 
3 to 51 days) among the control group (p=0.004).  Further, in-hospital visits were reduced 
for the remote monitored group (2.0 visits per patients per year) compared to the control 
group (3.2 visits per patient per year) for a 37.5% relative reduction (p<0.001).33 Lastly, 
data from the ALTITUDE survival study have shown that both CRT-D and ICD devices 
confer a survival benefit (HR 0.67, 95% CI: 0.64-0.69 for CRT-D devices, HR 0.57, 95% 
CI: 0.55-0.59 for ICD devices) when used with a remote monitoring network compared 
to those devices when not networked.34 
Today, enrollment in the CareLink® network is automatic, as patients are pre-
enrolled in the program when the device is implanted.  However, at the time the Medicare 
ICD registry was maintained (see below), only 39% of implanted devices utilized the 
CareLink® network, which significantly affected the number of patients available for 
study (Medtronic data on file, 2016). 
1.3.4 Relationship	between	Heart	Failure,	Atrial	Fibrillation,	Bi-
Ventricular	Pacing	Percentage,	and	Heart	Rate	Variability	
Atrial fibrillation is the most common sustained heart arrhythmia among adults, 
currently affecting between 2.7 and 6.1 million people in the US, and is expected to rise 
to 12.1 million by 2030.1  Heart failure (HF) and atrial fibrillation (AF) often manifest 
together.  Whether there is a causal relationship or whether this is coincidental due to 
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their common risk factors (e.g., hypertension, coronary artery disease, diabetes, and 
advancing patient age) is a subject of debate.  However, the clinical treatment of one 
condition often must consider the other.  For the purposes of this dissertation, the focus 
will be on AF in the context of cardiac resynchronization therapy (CRT) for the treatment 
of heart failure.  Specifically, a reduction in CRT efficacy has previously been found in 
the presence of AF due to the high prevalence of fusion and pseudo-fusion beats, 
resulting in poor ventricular capture by the device.35 This is a non-trivial issue in the 
treatment of HF via CRT as approximately 25% of patients eligible for CRT also have 
comorbid AF, even though nearly all previous studies of CRT efficacy have excluded 
patients with AF.36,37  Based on a meta-analysis of 23 studies representing 7,495 CRT 
patients, Wilton, et al., found that CRT effectiveness decreased among those with varying 
definitions of AF compared to those without. CRT nonresponse was 32% higher in the 
AF group (RR 1.32, 95% CI: 1.12-1.55), along with 50% higher all-cause mortality (RR 
1.50, 95% CI: 1.08-2.09). 38  However, the determination of whether a patient has AF can 
be difficult, especially in the cases of paroxysmal AF, and sporadic cases of persistent 
AF.  That is, a patient may not be in AF at the time they are examined by a clinician, and 
therefore cases may be missed during evaluation, yielding an underestimate of the true 
AF population among CRT patients.  CRT devices, however, continually monitor the 
amount of time a patient spends in AF, and reports it as a percentage of time.  This “AF 
Burden” variable can therefore be very quantitative in measuring and determining the 
effect of AF on patient outcomes.  In a 2012 study, Sarkar, et al. found that CRT patients 
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with left ventricular dysfunction and CRT device-quantified AF have a higher risk of 
heart failure hospitalization than those with no AF (HR 2.04, 95% CI: 1.5-2.7).39 They 
further found that a single day of high AF burden (more than 6 hours) in the previous 30 
days increased risk of HF hospitalization in the following 30 days (HR 3.4, 95% CI: 1.8-
6.2), indicating that even transient, potentially asymptomatic AF, which may easily be 
missed by clinical examination alone and misclassified as “no AF”, significantly affects 
patient outcomes. 
One common treatment for persistent, medically refractory AF is atrioventricular 
(AV) node ablation.  The AV node is a feature in the heart that conducts electrical signals 
from the sinoatrial (SA) node in the atrium, where the signaling of heart muscle 
contraction begins, to the ventricles.  Ablation effectively cuts off communication 
between the atria and the ventricles, stopping any conducted ventricular beats resulting 
from a spurious signal from the chaotically contracting atrium as is found in AF.  After 
AV node ablation, a CRT or pacemaker device is then required to maintain heart rhythm, 
since the sinoatrial node can no longer control ventricular contraction.  Many CRT 
devices can provide electrical stimulation to both ventricles of the heart separately.  The 
frequency at which the device provides bi-ventricular (bi-V) pacing to the heart has also 
been found to influence patient outcomes, with higher percentages of bi-V pacing leading 
to fewer hospitalizations and reduced mortality.  Koplan, et al., found that a bi-ventricular 
pacing percentage of greater than 92% led to a 44% reduction in the hazard rate of heart 
failure hospitalization when compared to those with less than 92% bi-ventricular pacing 
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(HR 0.56, p-value <0.001).40  Likewise, Hayes, et al., found that bi-ventricular pacing 
percentage affected patient outcomes, with those patients in the highest quartile (>99.6% 
pacing) having a 24% reduction in mortality (HR 0.76, p<0.001) compared to the lowest 
quartile (paced less than 94.8%).41   
In this case, knowledge of AV node ablations is essential to provide an appropriate 
estimate of associations between bi-V pacing percentages and outcomes, since those who 
have had an AV node ablation are necessarily bi-V paced 100% of the time.  Unless AV 
ablations are accounted for in the results, any observed association between bi-V pacing 
and hospitalization or death would likely be biased towards the null, as ablations 
effectively remove the previously reported associations between AF burden and % bi-V 
pacing.  In short, AV node ablation will be presumed to interact with % bi-V pacing in 
the analysis.  Highlighting the importance of knowing AV node ablation status, 
Gasparini, et al., have recently shown that among AF patients, AV node ablation is more 
effective in reducing total mortality among CRT patients than drugs alone (HR 1.55, 95% 
CI: 1.33-1.80) as well as cardiac mortality (HR 1.57, 95% CI: 1.37-1.88).  They also 
found that the rates of both of these events among AV node ablation patients with AF are 
no greater than for patients in sinus rhythm (p-values=0.79 and 0.95, respectively).42  
Neither the Koplan study, nor the Hayes study stated how they handled patients with AV 
node ablation. 
Lastly, increased atrial heart rate variability (HRV) is also known to improve 
outcomes of patients with heart failure, including CRT patients.43,44  CRT, in turn, has 
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itself also been shown to increase heart rate variability of patients over time.  In two 
studies by Adamson, et al, they found a statistically significant lowering of HRV of 30 
milliseconds for those patients implanted with a CRT device, but randomized to “CRT-
off” compared to those who had a CRT implanted in the “CRT-on” arm (p-value 0.02). 45  
In the second study, lower heart rate variability, as measured by the standard deviation 
between atrial cycle lengths (SDAAM) averaged over 5 minutes, was found to increase 
mortality risk--by 320% for low SDAAM values (<50ms) compared to those with high 
SDAAM values (>100ms).46  Further, Fantoni, et al., found that a similar measure, 
SDANN, which measures the standard deviation between intrinsic intervals averaged 
over a specific period of time also increased by a statistically significant 24 milliseconds 
three months after CRT implant compared to baseline.47  Importantly, Sarkar, et al. found 
that poor ventricular rate control modified the association between AF and outcomes, 
highlighting the importance of this study to consider the effects of all these variables 
simultaneously.39 
1.3.5 Hospitalization	Burden	in	Heart	Failure	
There is a significant burden to living with heart failure on the part of the patient, 
and managing such a patient on the part of the clinician, due to the need for frequent 
patient hospitalization.  Many patients experience severe, acute episodes of symptoms 
including fatigue, dyspnea, edema, sudden weight gain, and chest pain which require 
immediate treatment and/or hospitalization.  Dunlay, et al., found that after HF diagnosis, 
83% of patients were hospitalized at least once and 42.6% were hospitalized at least four 
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times over the follow up period (mean 4.7 years).48  The need for patient hospitalization 
is also associated with an increased rate of mortality, as well.  After adjusting for 
potential confounders, Setoguchi, et al., found statistically significant increases in 
mortality hazard rates for additional hospitalizations beyond the index hospitalization as 
shown below in Figure 6. 
 
Figure 6. – Effect of Number of HF Hospitalizations on Mortality 
 
There is also a significant cost burden to these hospitalizations, with costs 
estimated at over $23,000 for each HF-related hospitalization.49  Managing these costs for 
patients with HF is particularly challenging, as approximately 20% of patients are 
rehospitalized within 30 days of initial admission.50  However, with the advent of a 30-
day all-cause readmission penalty by the Centers for Medicare and Medicaid Services 
(CMS) in 2012, there is added incentive on the part of physicians and hospitals to reduce 
the frequency of these admissions, as such treatment may not be fully reimbursed. 
While several studies have identified device-measured diagnostic data as predictors 
of impending hospitalization events before an actual, initial hospitalization event51-54, a 
result of the institution of the CMS rehospitalization penalty has rather been to focus 
From Setoguchi S, Stevenson LW, Schneeweiss S. Am Heart J. 2007;154:260-6. 
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efforts on reducing 30-day readmissions for heart failure.  Several attempts have been 
made at identifying those at higher risk of readmission within 30 days based upon 
demographic, disease state, and device measured information available pre- or post-
admission, or at the time of discharge.55-57  
Whellan, et al., looked at a total of 208 patients from a combination of four studies 
who were hospitalized for HF-related causes during the follow up period.  Of the 166 
patients who had more than 30 days of follow-up information after discharge, 27 were 
hospitalized again within 30 days.  Device measured parameters from the first 7 days 
after discharge were used to generate a model which categorized risk according to intra-
thoracic impedance, AF burden, ventricular rate during AF, % bi-V pacing, and night 
heart rate.  This model then stratified patients into “high”, “medium”, and “low” risk 
categories based on their score. 
 
Figure 7. – Risk Stratification Scheme Based on Device Measured Parameters 
  
From Whellan DJ, Sarkar S, Koehler J, Small RS, Boyle A, 
Warman EN, Abraham WT. Am J Cardiol. 2013;111:79-84. 
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After adjusting for age, gender, and NYHA class, they found statistically 
significantly elevated hazard ratios for those with scores of 3+ versus those with scores of 
0 (HR 22.7, 95% CI: 3.2-161.7) or scores of 1-2 (HR 4.1, 95% CI: 2.0-8.4), indicating 
that patients who met more of the device-measured diagnostic criteria had significantly 
higher rates of 30-day rehospitalization.56  
Small, et al., developed a very similar model, but using device measured 
information on the day of discharge, as opposed to during the seven days following 
discharge.  Their model used slightly different criteria than the Whellan study, but was 
very similar in structure.  Those patients which met 2 or more of their diagnostic criteria 
(including intrathoracic impedance value > 8Ω, AF burden > 6 hours, CRT pacing < 
90%, and night heart rate > 80 bpm) were found to have a 4.4-fold higher rate of 30-day 
reshospitalization than those who met none of the diagnostic criteria (HR 4.4, 95% CI: 
1.6 – 12.0) and those who met one criterion had a 2.4-fold higher rate than those who met 
none (HR 2.4, 95% CI: 1.1 – 5.3).57  Both of these studies predict risk of 30-day 
rehospitalization after discharge, but are based on relatively small potentially 
heterogeneous cohorts, and few potential covariates were available when building their 
rehospitalization model.   
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2 Data	Sources	
For the period of January 2005 to April 2006, the Centers for Medicare and Medicaid 
Services (CMS) maintained a registry of patient information for recipients of new ICD 
and CRT-D devices from Medicare-reimbursed procedures.  This information included 
clinical characteristics, clinical history, patient demographic information and device-
related information.  This information has previously been merged with Medicare 
Provider Analysis and Review (MedPAR) data from the Medicare claims database to 
examine associations between clinical characteristics and patient outcomes on a 
population of 14,946 CRT-D patients.58  The MedPAR data contain information on 100% 
of Medicare beneficiaries using hospital inpatient services at certified hospitals.  
However, of note is that hospitalizations occurring for patients with health maintenance 
organization or managed care organization (HMO or MCO) coverage are not found in the 
Medicare utilization data.  These patients represent approximately 6% of the patients 
found in the Medicare MedPAR dataset.  Two separate analyses were performed for 
hospitalization outcomes in Manuscript 1 and Manuscript 2, below:  one excluding these 
patients from the analysis, and another keeping these patients in the dataset but adjusting 
for HMO/MCO status(yes/no), by adding it as another variable in the model.  Analyses 
for the mortality outcome in both Manuscripts 1 and 2 left all patients in the analysis, 
regardless of HMO/MCO status, as it is unlikely to affect mortality outcomes.  In 
Manuscript 3, all HMO/MCO patients were excluded from the analysis, as we 
   29 
 
specifically estimated risk of 30-day rehospitalization, and could significantly 
underestimate risk for those patients if they were left in the dataset. 
These data sources were joined with device information from the Medtronic 
CareLink® network.  The Medtronic CareLink® network contains information from 
21,012 unique devices (CRT and ICD devices) implanted during the January 2005 – 
April 2006 time frame for which CMS maintained records.  After removing ICD devices, 
and removing devices not found in the CareLink® database implanted in this time period, 
the combined CareLink®-Medicare dataset contained 7,702 Medtronic CRT patients 
enrolled in the CareLink® network which formed the final population for analysis.  Final 
numbers of patients analyzed varied depending on the analysis performed, the type of 
devices in the study population, and the features enabled on each device (for example, 
OptiVol® impedance monitoring is not available on every device). 
In order to protect patient privacy, the CMS data was matched on the basis of patient 
age at implant, patient gender, CRT-D device model, de-identified (3-digit) patient zip 
code, and date of device implant, rather than on a directly identifiable variable such as 
patient social security number or device serial number, which is considered protected 
health information under HIPAA.  The data resides at the University of Virginia – 
Charlottesville School of Medicine pursuant to the Data Use Agreement for the Medicare 
data.  Both the CMS data and Medtronic data were de-identified prior to the joining of 
the datasets.  The study was determined to be exempt from IRB review by the University 
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of Minnesota IRB under federal guidelines 45 CFR Part 46.101(b) category #4 “existing 
data; records review; pathological specimens.”  (Study number 1505E70742.) 
All of the Carelink® data used in this dissertation are by necessity only from 
Medtronic manufactured devices.  Table 3 below compares demographics and clinical 
characteristics of patients who have received a Medtronic device to those who received a 
device from another manufacturer.  Differences between Medtronic and non-Medtronic 
CRT patients are small, and are not expected to be of practical significance.  We 
therefore believe that the findings of these manuscripts are extensible to the broader 
CRT-eligible heart failure population.  
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Table 3. – Baseline Demographics for Medicare CRT Patients by Device Manufacturer Group 
 All Medicare CRT 
Patients(n=14,902) 
Medtronic CRT 
Patients (n=7,702) 
Non- Medtronic CRT 
Patients (n=7,200) 
Age, mean ±SD, y 73.0±10.5 73.1 ±10.3 72.9±10.7 
Duration HF, mean ±SD, y 24.7±25.4 25.1±25.4 24.3±25.4 
LVEF, mean ±SD, % 23.1±6.3 23.0±6.3 23.3±6.3 
QRS duration, mean ±SD, 
ms 
156.8±24.9 157.8±24.7 155.8±25.0 
SBP, mean ±SD, mm Hg 126.5±22.4 125.8±21.9 127.3±22.9 
DBP, mean ±SD, mm Hg 70.2±13.7 70.0±14.5 70.3±12.9 
Heart rate, mean ±SD, bpm 72.0±18.0 72.0±17.8 72.0±18.2 
Gender, n(%)    
Female 27.3 27.0 27.7 
Male 72.7 73.0 72.3 
NYHA class, n(%)    
I 1.2 1.2 1.2 
II 11.0 11.0 11.0 
III 74.1 74.6 73.7 
IV 13.7 13.3 14.1 
Ischemic CM, n(%) 69.2 67.9 70.5 
Prior CABG, n(%) 42.0 41.7 42.2 
Atrial fibrillation, n(%) 34.7 36.1 33.2 
Ventricular tachycardia, 
n(%) 
19.6 20.3 18.9 
Sudden cardiac arrest, n(%) 1.7 1.8 1.7 
Diabetes mellitus, n(%) 35.7 35.3 36.2 
Prior MI, n(%) 50.9 49.8 52.0 
Smoker Status, n(%)    
Never 42.3 42.4 42.1 
Former 48.6 48.9 48.4 
Current 9.1 8.7 9.5 
Medications, n(%)    
b-blocker 78.9 79.2 78.6 
ACEI or ARB 74.3 74.6 73.9 
Digoxin 41.7 41.3 42.1 
Diuretic 78.7 79.9 77.4 
Amiodarone 13.6 13.9 13.3 
Warfarin 31.8 33.1 30.4 
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3 Manuscript	1	–	Association	of	Exceeding	Intrathoracic	
Impedance	Threshold	on	Patient	Mortality	and	
Hospitalization	
3.1 Overview 
Objective: To determine adjusted associations among OptiVol® threshold crossings, 
long-term survival and hospitalizations among heart failure (HF) patients with Medicare 
coverage in the United States.  Background:  The long-term prognostic value of 
OptiVol® crossings on clinical events and mortality in real-world patients with cardiac 
resynchronization therapy defibrillators (CRT-D) is uncertain.  Methods: A cohort with 
OptiVol®-enabled CRT-D devices from the Implantable Cardioverter Defibrillator 
Registry was linked to both Medicare claims/summary data and Medtronic’s CareLink® 
Network data.  An extended multivariable Cox model was used to analyze associations 
among OptiVol® threshold crossings (treated as time-dependent covariates), mortality, 
and HF-related hospitalizations (HFH). 
Results: We analyzed N= 1,565 patients with OptiVol®-enabled CRT-D devices (mean 
age 72.8, 28% women). Median follow-up was 6.3 years. Patients with >15.1% of days 
above OptiVol® threshold (highest quartile) had more than a 4-fold increase in mortality 
(HR 4.2, 95%CI:  3.3-5.3) and more than a 3-fold increase in HFH (HR 3.2, 95%CI: 2.4-
4.2) compared with patients having <4.1% of days above threshold (lowest quartile) after 
adjustment for key covariates.  In addition, a single OptiVol® crossing was associated with 
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both a significantly increased mortality rate (HR 1.87, 95% CI: 1.27-2.75) and HFH rate 
(HR 1.70, 95% CI: 1.28-2.27). 
Conclusion: In a CRT-D cohort with over 6 years of follow-up, both single OptiVol® 
crossings and time above OptiVol® threshold were associated with increased rates of 
mortality and hospitalization, which has important implications for clinical care. This is 
the first study integrating device data with Medicare outcomes to validate the long-term 
significance of OptiVol® findings. 
3.2 Introduction 
Treatment and management of heart failure (HF) in the US remains a major public 
health burden, with 5.7 million patients suffering from the disease, many of them facing a 
poor prognosis.  These patients are hospitalized over 1 million times a year, and are often 
hospitalized on multiple occasions throughout their treatment. 1    Therefore, predicting 
death and future hospitalizations in these patients is a highly desirable goal.  One strategy 
to do so, intrathoracic impedance monitoring, has been shown to be safe and effective for 
cardiac resynchronization therapy defibrillator (CRT-D) patients in clinical trials.20-24,59,60  
While these trials have shown some predictive power of future adverse events when a 
pre-programmed threshold value is reached, limitations have included a lack of 
adjustment for patient characteristics and comorbid conditions, shorter follow-up times, 
the need for external validation in a real-world cohort, and inclusion of threshold 
crossings occurring only during the first 6-months of follow-up.25 
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In the current era, the use of intrathoracic impedance monitoring in the clinical 
setting remains controversial.  There remains debate regarding not only which specific 
clinical actions should be taken in response to device readings in order to avoid adverse 
outcomes, but also whether device-measured information should be used alone or in 
combination with an in-person clinical evaluation.61  Another methods for monitoring HF 
patients, pulmonary artery pressure monitoring, has shown some promise in preventing 
decompensation-related hospitalization when guided by a specific management 
strategy62, but requires implantation of additional hardware.  Additional long-term data 
demonstrating the independent impact of intrathoracic impedance monitoring on clinical 
outcomes in a real-world cohort would be of great interest with respect to the value of 
this strategy.  In order to address this unmet need, we examined the impact of OptiVol® 
threshold crossings and the time above threshold on long-term survival and HF-related 
hospitalizations after adjusting for key covariates in a large population of patients with 
Medicare coverage with over 6 years of follow-up.	
3.3 Methods 
3.3.1 Study	Population	
For this analysis, we used data from the Medicare Implantable Cardioverter-
Defibrillator (ICD) Registry with an OptiVol®-enabled CRT-D device. The Center for 
Medicare and Medicaid Services (CMS) requires providers who implant ICDs, including 
CRT-Ds, to record various patient demographic, clinical, and device information. For the 
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period of January 2005 to April 2006, the registry was maintained by the Iowa 
Foundation for Medical Care and is available for download from CMS (See 
https://www.cms.gov/Medicare/Medicare-General-
Information/MedicareApprovedFacilitie/Downloads/icdregistry1.pdf for more 
information).   Starting in April 2006, this function was transferred to the American 
College of Cardiology in the form of the National Cardiovascular Data Registry (NCDR).  
Therefore, the Medicare registry data used for this analysis were all from this 14-month 
time period.  These registry data were previously linked with MedPAR claims data to 
ascertain time from device implant until hospitalization and patient death. 58  These data 
were further linked with Medicare Master Beneficiary Summary File data to determine 
Medicare enrollment and type of coverage.    
We then linked these Medicare data with CareLink® data regarding patient 
monitoring.  The CareLink® network was established in 2002 as a de-identified database 
containing longitudinal device-programmed and device-measured information on 
Implantable Cardiac Monitor (ICM), Implantable Pulse Generator (IPG), Implantable 
Cardioverter-Defibrillator (ICD), and Cardiac Resynchronization Therapy with 
Defibrillator (CRT-D) devices manufactured by Medtronic in the United States and is 
still ongoing.   To align with the timeframe of available Medicare data, the CareLink® 
database was queried to find all CRT-D devices equipped with the OptiVol® feature 
implanted in the US between Jan 1, 2005 and Apr 30, 2006.  Some devices equipped with 
the OptiVol® feature, however, did not actually have the feature “turned-on” in the 
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device.  Information from devices with actual CareLink® transmissions was then linked 
with the Medicare data on the basis of device implant date (±2 days), patient age at 
implant (±1 year), patient sex, device model, and de-identified (3-digit) ZIP code.  Patient 
mortality and hospitalization follow-up information was available through December 
2011.  A pictorial representation of how the data were merged is shown in Figure 8.  
Patients who had a CRT-D device implanted, but were outside the established indication 
guidelines at the time to receive such a device (NYHA HF Class III or IV, QRS interval ≥ 
120 ms and a left ventricular ejection fraction (LVEF) ≤ 35%) were excluded from the 
Medicare dataset.63   In addition to the variables used for linking the two databases, the 
time until a device experienced an OptiVol® threshold crossing and time above threshold 
were also taken from the CareLink® registry.  Patients were followed up until end of 
Medicare enrollment or time of the last CareLink® record if they did not experience any 
threshold crossing. A total of 1,565 patients were matched between the Medicare data 
and the CareLink® registry. 
3.3.2 Endpoint	Definition	
Heart failure hospitalization in the Medicare dataset was determined by an 
inpatient admission with a primary ICD-9-CM diagnosis code of 428.x.  For mortality 
endpoints, the available MedPAR data contained only all-cause mortality and not 
underlying cause of death.   
3.3.3 Exposure	Definition	
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The CareLink® database was queried to determine when an OptiVol® threshold 
was exceeded.  The CareLink® database contains information OptiVol® threshold 
setting and the accumulated fluid index value.  These values were examined on a daily 
basis, and the first instance of the accumulated fluid index value being greater than the 
programmed OptiVol® threshold value was considered to be the time of threshold 
crossing.  Although the threshold value can be programmed to various values, the time 
until the first crossing was defined when the OptiVol® fluid index value exceeded the 
programmed value, independently of the threshold value setting used. 
 
3.3.4 Covariates	
Other variables in the Medicare registry that were considered in this analysis 
included patient age, sex, duration of HF, LVEF, QRS duration, systolic blood pressure, 
diastolic blood pressure, heart rate, NYHA class, presence of ischemic cardiomyopathy, 
bundle-branch block morphology, prior coronary artery bypass graft, atrial fibrillation 
(AF), anticoagulation therapy for AF, presence of ventricular tachycardia, prior sudden 
cardiac arrest event, diabetes mellitus, prior myocardial infarction, smoking status, 
chronic kidney disease (CKD), end-stage renal disease (ESRD), and the prescription of 
beta-blockers, ACE-inhibitors or angiotensin receptor blockers, digoxin, diuretics, 
amiodarone, and/or warfarin.  The diagnosis of chronic kidney disease (CKD) and end-
stage renal disease (ESRD) was established based on administrative diagnosis codes from 
inpatient and outpatient encounters, available in CMS utilization files from the year the 
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device was implanted.  All of the other covariates were input by each patient’s provider at 
the time of implant to the CMS’ ICD Abstraction Tool, and were contained in the 
Medicare ICD registry data. 
While the main exposure of interest was time until first threshold crossing, a 
patient may experience many such events over their follow-up time, or may have 
extended periods of time above the threshold, indicating a chronic congestive condition.  
To capture this phenomenon, we counted the number of days an individual patient spent 
with a fluid index value above the threshold in CareLink® prior to their first clinical 
endpoint.    Days above threshold could be caused by either multiple crossings or by 
extended periods of time for a single crossing, or both.  Patients were then categorized 
into quartiles based on this parameter. 
3.3.5 Statistical	Analysis	
Extended Cox models were run using PROC PHREG in SAS software, version 
9.4 (SAS Institute, Cary, NC) to account for the time-dependent nature of the exposure 
variable of interest, time to OptiVol® threshold crossing.  With increasing follow-up 
time, patients who experienced a threshold crossing move from the “no crossing” group 
to the “crossing” group.  The extended Cox method accounts for this change in exposure 
status, adjusting the exposure group sample sizes appropriately at the time of each 
event.64  Analyses for hospitalization endpoints were run both with cause-specific 
models, where all competing outcomes other than hospitalization (namely, patient death) 
were censored, as well as competing risk (or subdistribution) models, where patients who 
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died were left in the denominator to estimate actual observable patient hospitalization 
rates.65  Models were run first as a minimally-adjusted analysis, only including patient 
age at implant and patient sex.  Where HF-related hospitalization outcomes were 
examined, we also adjusted for whether the patient had supplemental health maintenance 
organization (HMO)/ managed care organization (MCO) coverage.  Fully adjusted 
models were then also developed, based on all of the available Medicare ICD Registry 
variables. Because data on hospitalizations from patients enrolled in HMO or MCO can 
be incomplete, we performed a sensitivity analysis in which we excluded patients with 
any indication of HMO or MCO coverage, as determined from Medicare annual 
summary data.  We further explored whether either patient race or sex would modify the 
association observed between OptiVol® threshold crossing and mortality or HF-related 
hospitalization by adding interaction terms to each of these models. 
 For Kaplan-Meier plots based on threshold crossings, we applied the method of 
Simon and Makuch to account for the time-dependent nature of threshold crossings.  Per 
this method, the data for each individual were split to account for time a patient spent in 
the “no crossing” group before a threshold crossing occurred.  An individual patient’s 
data therefore shows up in both groups, contributing their associated amount of time in 
each group before an outcome event or censoring occurs.66,67   
Lastly, we determined the number of days each patient spent above the programmed 
threshold value, if any, from CareLink®, and calculated the percentage of their follow-up 
time each individual patient spent above threshold. This could have come in the form of a 
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single, prolonged crossing event, or through several acute crossing occurrences. Patients 
were then grouped into quartiles (<4.1%, 4.1-8.3%, 8.3-15.1%, >15.1%) and those in the 
highest quartile (>15.1% of days above threshold) were compared to those in the lowest 
quartile. 
3.4 Results 
Table 4 shows the subset of patients analyzed in this study compared to those in the 
Medicare dataset who were not examined (those without Medtronic devices, or those who 
could not be matched in the database).  Patient characteristics were similar in those 
patients who were analyzed versus those who were not analyzed, although some 
statistically significant differences were obtained because of the large number of patients 
studied. 
In our retrospective cohort study, we linked 1,565 patients between the CareLink® 
database, Medicare ICD registry, and Medicare claims data.  Over the median 6.3 year 
follow-up period, we observed a mortality rate of 8.8 deaths per 100 person-years (706 
deaths/8,037 person-years), and a HF-related hospitalization rate of 9.2 hospitalizations 
per 100 person-years (608 cases/6,581 person-years).  There were a total of 1,514 patients 
(97%) who experienced an OptiVol® threshold crossing event during follow up, with 
their distribution over time shown in Figure 9.  Median time to threshold crossing was 
10.5 months.  A threshold crossing value of 60 Ohm-days was programmed in 99.2% of 
devices. 
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As shown in Table 5, an OptiVol® threshold crossing at any point in the life of the 
device was associated with an 87% increase in patient mortality (HR 1.87, 95% CI 1.27-
2.75) after adjusting for patient sex, patient age at implant, ischemic cardiomyopathy, 
CKD, smoking status, and the prescription of digoxin, compared to those patients who have 
not had a threshold crossing by that same time.  Hazard ratios for all statistically significant 
variables are given in Table 7.  We examined the effect of race in this analysis, but it was 
found not to be a significant predictor of mortality and was therefore dropped from the 
models.  Figure 10 shows that unadjusted Kaplan-Meier survival probabilities comparing 
mortality between the “Threshold Crossing” group to the “No Crossing” group were 
statistically significant (log-rank test, p-value < 0.0001). Of note, individual patients 
contributed follow-up time to both curves if they experienced a threshold crossing:  the 
time until threshold crossing was accounted for in the “no-crossing” group, and any time 
after such a crossing was accounted in the “crossing” group until either patient death or 
censoring occurred.   
For hospitalization outcomes, the extended Cox model showed that an OptiVol® 
threshold crossing was associated with a 70% higher rate of HF-related hospitalization (HR 
1.70, 95% CI: 1.28-2.27) when adjusting for these same covariates, including whether 
patients had private health coverage through an HMO or MCO organization, which was 
added as an additional variable in the model. In the Kaplan-Meier plot shown in Figure 11, 
the log-rank statistic comparing the “Threshold Crossing” group to the “No Crossing” 
group was again statistically significant (p-value < 0.0001). When excluding the 
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HMO/MCO covered patients from the dataset, the association calculated by the extended 
Cox model was slightly attenuated (HR 1.63, 95% CI: 1.22-2.19).   We again examined the 
effect of race, but it was not found to be a significant predictor of HF-related 
hospitalizations, and was therefore dropped from the models. 
We further explored whether there was any modification of the association between 
OptiVol® threshold crossing and the outcomes by either race or patient sex. For mortality 
outcomes, we found no significant interactions between threshold crossing status and either 
sex (p-value = 0.49) or race when its main effect was left in the model (p-value = 0.99). In 
contrast, the patient’s sex significantly modified the association of threshold crossing with 
HF-related hospitalization (p-value = 0.01 to 0.03) based on a stronger association between 
OptiVol® status and HF-related hospitalization in men (regardless of whether HMO/MCO 
patients were included or excluded, or the survival model used). There was not a significant 
interaction for race (p-value = 0.90) for hospitalization outcomes when leaving the main 
effect in the model. The results stratified by sex are presented in Table 6. 
Since patients are at risk of experiencing multiple threshold crossings over their 
follow-up time, we also examined the effect of each individual patient’s time above the 
pre-programmed threshold as a percentage of their total follow up time.  These percentages 
were categorized into quartiles, and their survival plots are shown in Figure 12 and Figure 
13, showing significant differences across the quartiles (log-rank test, p-value <0.0001).  
In a multivariable Cox model with the same covariates as performed above, but removing 
the threshold crossing variable, the quartile of percent follow-up time above threshold was 
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statistically significant for both mortality and HF-related hospitalization outcomes (both p-
values <0.0001).  In this model, patients with > 15.1% of follow-up days above the 
OptiVol® threshold (highest quartile) had more than a 4-fold increased mortality rate (HR 
4.2, 95%CI: 3.3-5.3), and more than a 3-fold rate of HF-related hospitalization (HR 3.2, 
95% CI: 2.4-4.2) than those patients in the lowest quartile compared with those in the 
lowest quartile (< 4.1% of days above threshold). 
3.5 Discussion 
In this large cohort of patients with CRT devices linked to Medicare data followed 
for a median of over 6 years, patients who had more than 15.1% of follow-up days above 
threshold (representing 25% of patients in the entire cohort) had a more than 4-fold 
increased mortality rate and a more than 3-fold increased HF-related hospitalization rate 
after adjustment during more than 6 years of follow up compared with the 25% of 
patients who had <4.1% of days above threshold.  In addition, a single OptiVol® 
threshold crossing was associated with significantly increased rates of both patient 
mortality (87%) and patient HF-related hospitalization (70%).  These results were robust 
to the statistical analysis used and whether patients with HMO/MCO coverage were 
excluded.  Although the impact of OptiVol® threshold crossing had a clinically 
significant impact on survival in both genders, we did find that an OptiVol® threshold 
crossing was associated with an increased rate of HF-related hospitalization in men but 
not in women.  Previous studies either lacked hospitalization outcome information, 
covariate information, or were insufficiently powered to detect this interaction. However, 
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this observed difference between the strength of the threshold crossing-hospitalization 
outcome for men and women is important and likely warrants further study. 
The association between OptiVol® threshold crossing, indicating accumulating 
fluid, and worsening HF is perhaps an obvious one, but has not been validated before in a 
real-world setting in the context of a large cohort.  The present study offers important 
new findings including associations with long-term clinical outcomes.  First, the 
Medicare data provided data on HF-related hospitalizations in addition to mortality.  
Second, the Medicare registry data also provided the opportunity to adjust for significant 
patient covariates and comorbid conditions, which resulted only in small differences in 
hazard ratio estimates versus the minimally-adjusted analysis.  Third, the present study is 
an improvement on previous work in that it considered Optivol® threshold crossing as a 
time-dependent variable.   Previous publications examined only those patients with an 
Optivol® threshold crossing during the first six months after device implant, effectively 
treating a patient with a crossing 1 day after implant as contributing the exact same 
follow up time to the “crossing” group as a patient with a crossing 6 months after 
implant.25 
Our data matching scheme linked about 20.4% of the available 7,670 Medicare 
CRT patients.  This proportion was limited in two major ways:  first, few device models 
implanted in the time frame of the Medicare ICD registry were available with the 
OptiVol® feature which was introduced beginning in April 2005.  As a result, 4,035 
(52.6%) devices in our cohort were of a device model which had the OptiVol® feature.  
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Second, at the time of the Medicare ICD Registry, enrollment in the CareLink® network 
was not automatic, and is estimated that 39% of Medtronic CRT devices implanted in this 
timeframe were actually enrolled in the CareLink® network (Medtronic data on file, 
2016).  We therefore estimate that approximately 1,600 devices of a type with OptiVol® 
available also enrolled in the CareLink® Network would exist in the available Medicare 
data.  Based on this estimate, our actual linkage (1,565 patients, or 20.4% of available 
Medicare data) is deemed reasonable. 
With respect to the clinical impact of our findings, our data show that both a single 
OptiVol® crossing and time above OptiVol® threshold are associated with markedly 
elevated rates of patient mortality and patient hospitalization in real-world practice.  
Those patients with >15.1% of day above threshold are of particular concern, as these 
patients have more than 4-fold increased risk of mortality and more than a 3-fold risk of 
HF-related hospitalization after adjustment during more than 6 years of follow up 
compared with the 25% of patients who have < 4.1% of days above threshold.  These 
patients, in particular, may benefit from more intensive medical management, including 
re-assessment of adherence to medical therapy, dietary recommendations, and CRT 
pacing percentage.  The strong association between intrathoracic impedance monitoring 
and outcomes in this cohort suggests that interventions designed to improve clinical 
outcomes based on intrathoracic impedance monitoring could be developed and tested in 
randomized clinical trials with a similar design to that of pulmonary artery pressure 
monitor trials.62  In summary, the findings of the present study suggest that OptiVol® has 
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the clinical predictive value necessary to improve clinical outcomes for HF patients, and 
that the pressing need is to develop an optimal interventional strategy based on OptiVol® 
findings.  
Limitations of this analysis include our inability to account for what specific clinics 
do with threshold crossing information.  Some clinics may be more likely to actively 
intervene when a threshold crossing is reached, by using the information to inform 
management without an actual in-person evaluation, while some may be more likely to 
hospitalize patients.  The net effect of this is that our hazard ratio for hospitalization after 
a threshold crossing may be biased downwards in clinics with aggressive outpatient 
management practices, and biased upwards in clinics with aggressive hospitalization 
practices.  Even so, this analysis represents “real-world” usage, and should give a clear, 
aggregate picture of the effect of a threshold crossing. In addition, the findings with 
respect to survival reflect a hard endpoint not directly influenced by variation among 
clinics.  Also, recent changes to Medicare reimbursement practices, incentivizing 
hospitals to treat heart failure in an outpatient setting may affect how current patients are 
managed versus how they were managed during the follow-up period of this study. 
Of note, both the Medicare and CareLink® databases were de-identified prior to 
our joining them together; however, based on the combination of five variables used to 
join the data sources together, we have shown that the likelihood of proper Medicare-
CareLink® linkage is excellent, since the actual sample size of our cohort matches what 
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was expected given the constraints of OptiVol® functionality and CareLink® enrollment 
at the time. 
In conclusion, both the occurrence of a single OptiVol® threshold crossing and the 
time above threshold are very strong predictors of patient survival and HF-related 
hospitalization after adjustment for key covariates in a large Medicare cohort of CRT-D 
patients.   This represents the first time that these OptiVol® findings have been 
associated with long-term clinical outcomes including all-cause mortality and HF-related 
hospitalization after adjustment for a complete range of covariates.  Gender-specific 
associations between OptiVol® findings and HF-related hospitalizations warrant further 
study. 
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3.6 Tables and Figures 
Table 4. – Baseline Demographics for Medicare CRT Patients by Analysis Cohort 
 All Medicare CRT 
Patients(n=14,935) 
Analysis Cohort 
(n=1,565) 
Non- Analyzed 
Cohort (n=13,370) 
p-value* 
Age, mean ±SD, y 73.0±10.5 72.8±8.1 73.1±10.7 0.24 
Duration HF, mean 
±SD, y 
24.7±25.4 24.1±24.4 24.8±25.5 0.33 
LVEF, mean ±SD, % 23.1±6.3 23.6±6.3 23.1±6.3 0.002 
QRS duration, mean 
±SD, ms 
156.8±24.9 157.8±24.7 156.7±24.9 0.11 
SBP, mean ±SD, mm 
Hg 
126.5±22.4 126.1±21.3 126.5±22.5 0.52 
DBP, mean ±SD, mm 
Hg 
70.2±13.7 69.9±12.6 70.2±13.8 0.38 
Heart rate, mean ±SD, 
bpm 
72.0±18.0 71.3±14.0 72.1±18.4 0.03 
Sex, n(%)     
Female 27.3 28.2 27.2  
Male 72.7 71.7 72.8 0.39 
NYHA class, n(%)     
I 1.2 1.1 1.2  
II 11.0 10.4 11.1  
III 74.2 77.0 73.8 0.04 
IV 13.6 11.6 13.9  
Ischemic CM, n(%) 69.2 62.8 69.9 <0.001 
Prior CABG, n(%) 42.0 39.1 42.3 0.02 
BBB Morphology, 
n(%) 
 
 
   
LBBB 69.3 71.4 69.1  
RBBB 11.0 9.7 11.1 0.13 
Other IVCD 19.8 18.9 19.8  
Atrial fibrillation, 
n(%) 
34.7 35.2 34.6 0.63 
Ventricular 
tachycardia, n(%) 
19.6 17.0 19.9 0.01 
Sudden cardiac arrest, 
n(%) 
1.7 1.5 1.7 0.54 
Diabetes mellitus, 
n(%) 
35.7 34.9 35.8 0.49 
Prior MI, n(%) 50.9 45.8 51.4 <0.001 
Chronic Kidney 
Disease, n(%) 
32.0 26.8 32.6 <0.001 
End Stage Renal 
Disease, n(%) 
3.1 1.8 3.2 <0.001 
Smoker Status, n(%)     
Never 42.3 44.2 42.1  
Former 48.6 47.0 48.8 0.28 
   49 
 
Current 9.1 8.9 9.1  
Medications, n(%)     
b-blocker 78.9 80.3 78.7 0.17 
ACEI or ARB 74.3 77.8 73.9 <0.001 
Digoxin 41.7 40.8 41.8 0.44 
Diuretic 78.7 79.9 78.5 0.21 
Amiodarone 13.6 10.5 13.9 <0.001 
Warfarin 31.8 33.7 31.6 0.09 
*p-value comparing analyzed cohort to non-Analyzed cohort.  
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Table 5. – Associations between OptiVol® Crossing Status and Patient Mortality and 
Hospitalization 
 Minimally 
Adjusted*  
Cause-specific 
HR (95% CI) 
Minimally 
Adjusted* 
Subdistribution 
HR (95% CI) 
Fully Adjusted† 
Cause-Specific 
HR (95% CI) 
Fully Adjusted† 
Subdistribution 
HR (95% CI) 
Mortality 2.03 (1.38-3.00) N/A 1.87 (1.27-2.75) N/A 
HF related Hospitalization 
(including HMO/MCO 
patients) 
1.84 (1.38-2.45) 1.86 (1.37-2.52) 1.70 (1.28-2.27) 1.75 (1.30-2.37) 
HF-related Hospitalization 
(excluding HMO/MCO 
patients) 
1.75 (1.31-2.35) 1.77 (1.30-2.42) 1.63 (1.22-2.19) 1.68 (1.24-2.29) 
*Adjusted for patient age at implant, sex, and for hospitalization events, any HMO/MCO 
coverage (Y/N).  †Adjusted for pa9ent age at implant, sex, ischemic cardiomyopathy, chronic 
kidney disease, digoxin, smoking status, and for hospitalization events, any HMO/MCO coverage 
(Y/N). 
 
Table 6. – Interaction between OptiVol® Crossing Status and Patient Sex 
 
Fully Adjusted* 
Cause-specific HR 
(95% CI) 
Fully 
Adjusted* 
Overall 
Interaction 
p-value 
Fully Adjusted* 
Subdistribution 
HR (95% CI) 
Fully Adjusted* 
Overall 
Interaction 
p-value 
Mortality     
Male 
Female 
1.76 (1.16-2.66) 
2.46 (0.99-6.10) 
0.49 N/A N/A 
HF related Hospitalization 
(including HMO/MCO 
patients) 
    
Male 
Female 
1.92 (1.42-2.61) 
1.18 (0.78-1.77) 
0.02 
1.96 (1.42-2.70) 
1.26 (0.83-1.90) 
0.03 
HF-related Hospitalization 
(excluding HMO/MCO 
patients) 
    
Male 
Female 
1.86 (1.36-2.54) 
1.12 (0.74-1.69) 
0.01 
1.89 (1.36-2.62) 
1.20 (0.79-1.82) 
0.03 
* Adjusted for patient age at implant, sex, ischemic cardiomyopathy, chronic kidney disease, 
digoxin, smoking status, and for hospitalization events, any HMO/MCO coverage (Y/N). 
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Table 7. – Hazard Ratios for Patient Mortality and Hospitalization with and without 
Competing Risks and Patient HMO/MCO Status 
 
Hazard Ratio 
for Patient 
Mortality 
Cause-specific Hazard Ratio for 
Heart Failure-related 
Hospitalization 
Subdistribution Hazard Ratio for 
Heart Failure-related 
Hospitalization 
Including 
Medicare 
HMO/MCO 
Patients 
Excluding 
Medicare 
HMO/MCO 
Patients 
Including 
Medicare 
HMO/MCO 
Patients 
Excluding 
Medicare 
HMO/MCO 
Patients 
# of events 
705 608 561 
607 (327 
competing) 
561 (276 
competing) 
Follow up time 
(person-years) 
8,036 6,581 5,825 6,581 5,825 
Threshold 
crossing 
1.87 (1.27-2.75) 2.04 (1.49-2.80) 1.93 (1.42-2.68) 1.75 (1.30-2.37) 1.68 (1.24-2.29) 
Chronic Kidney 
Disease (Y vs N) 
2.08 (1.78-2.43) 2.38 (2.00-2.78) 2.33 (1.96-2.78) 2.17 (1.85-2.63) 2.17 (1.82-2.56) 
Sex (Female) 0.76 (0.63-0.92) 0.91 (0.75-1.11) 0.88 (0.72-1.08) 0.94 (0.77-1.15) 0.91 (0.74-1.12) 
Ischemic 
Cardiomyopathy 
(N vs Y) 
1.33 (1.12-1.59) 1.15 (0.96-1.37) 1.14 (0.93-1.37) 1.10 (0.92-1.32) 1.09 (0.90-1.32) 
Age at Implant 
(years) 
1.04 (1.03-1.05) 1.01 (1.00-1.02) 1.01 (1.00-1.02) 1.01 (1.00-1.02) 1.01 (1.00-1.02) 
Smoking Status       
(Current vs 
Never) 
1.33 (1.01-1.76) 1.31 (0.98-1.76) 1.18 (0.86-1.61) 1.30 (0.96-1.77) 1.17 (0.85-1.62) 
(Former vs 
Never) 
1.23 (1.05-1.44) 1.28 (1.08-1.53) 1.19 (1.00-1.42) 1.27 (1.06-1.51) 1.18 (0.98-1.41) 
Digoxin (Y vs N) 1.23 (1.06-1.45) 1.19 (1.01-1.41) 1.16 (0.98-1.37) 1.16 (0.98-1.37) 1.14 (0.95-1.35) 
Any HMO/MCO 
coverage (Y vs N) 
N/A 0.76 (0.56-1.02) N/A 0.69 (0.52-0.93) N/A 
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Figure 8. – Cohort Selection and Data Merging Scheme 
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Figure 9. –  Kaplan-Meier Plot of Time Until OptiVol® Threshold Crossing 
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Figure 10. – Kaplan-Meier Plot of Time Until Patient Mortality by Threshold Crossing 
Status 
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Figure 11. – Kaplan-Meier Plot of Time Until Patient Hospitalization for Heart Failure by 
Threshold Crossing Status 
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Figure 12. – Kaplan-Meier Plot of Time until Patient Mortality by Percent Follow-up Above 
Threshold Quartile 
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Figure 13. – Kaplan-Meier Plot of Time until HF-related Hospitalization by Percent Follow-
up Above Threshold Quartile 
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4 Manuscript	2	–	Association	of	Baseline	Biventricular	
Pacing	Percentage,	AF	Burden,	and	Heart	Rate	
Variability	with	Mortality	and	Rates	of	Hospitalization	
in	Patients	with	HF	and	CRT	
4.1 Overview 
Objective: To examine associations of bi-ventricular pacing percentage with time 
until patient death and HF-related hospitalization after adjusting for AVN ablation status, 
AF burden, and heart rate variability in CRT-D patients.  Further, to determine whether 
any association of bi-ventricular pacing with the endpoints of interest is modified by 
AVN ablation status, AF burden or heart rate variability.  
Background: Though bi-ventricular pacing percentage, AVN ablation status, AF burden 
and heart rate variability have previously been associated with outcomes in patients with 
HF, no studies in real-world practice have investigated them simultaneously or assessed 
their interactions. Methods: A cohort of Medicare CRT-D patients was formed by 
linking Medtronic CareLink® data with Medicare ICD registry, claims, and beneficiary 
file data with follow-up of over 6 years.  Extended Cox proportional hazards regression 
models were run to examine the associations of baseline device-measured bi-ventricular 
pacing, AF burden, heart rate variability, and their interactions, adjusting for a range of 
clinical covariates with all-cause patient mortality and heart failure-related 
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hospitalization. Results: We analyzed N= 2,625 patients with CRT-D devices (mean age 
73.1, 27% women). Median follow-up was 6.4 years. Patients with <99% bi-V pacing 
had increased rates of mortality and HF-hospitalization compared to those with ≥99% bi-
V pacing after multivariable adjustment (HR: 1.28, 95% CI: 1.14-1.45 and HR: 1.27, 
95%CI: 1.11-1.43, respectively). However, a complex set of interactions was found 
between bi-V pacing and AF, as well as HRV and AVN ablation.  Across several 
analytical scenarios, the presence of <99% bi-V pacing was associated with a 33% higher 
mortality rate compared to those with ≥99% bi-V pacing (HR 1.33, 95%CI: 1.16-1.52) 
among those without AF, while bi-V pacing was not associated with mortality in those 
with AF (HR 1.05, 95%CI: 0.81-1.35, comparing <99% to ≥99% bi-V pacing).  Findings 
were similar for heart failure-related hospitalization rates.   Also, the association of AVN 
ablation with outcomes was different across levels of HRV at baseline, with a 3.6-fold 
higher mortality rate after AVN ablation among those in the highest HRV quartile (HR 
3.6, 95%CI: 1.99-6.50), but no increased risk in those with low HRV.  Conclusion: In a 
Medicare cohort of CRT patients with over 6 years of follow-up, <99% bi-V pacing 
percentage was associated with an increased rate of mortality and hospitalization among 
those with no baseline device-measured atrial fibrillation.  In addition, AVN ablation was 
associated with worse outcomes among those with high baseline HRV, suggesting that 
the potential loss of benefits of higher HRV must be weighed when performing an AVN 
ablation procedure. This is the first study integrating device data with Medicare outcomes 
to validate the long-term significance of these variables together in this population. 
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4.2 Introduction 
An active area of research and controversy in the treatment of heart failure (HF) 
lies in how CRT patients with AF should be handled, as approximately 20-25% of CRT 
patients have comorbid AF, and nearly all previous randomized controlled CRT trials 
have excluded patients with AF.36,42,68  Device pacing of CRT patients with AF presents 
challenges due to the occurrence of fusion and pseudo-fusion beats, where the intrinsic 
cardiac electrical signal and the electrical impulse from the implanted device coincide to 
alter the QRS morphology.  This, in turn, reduces the effective percentage of CRT 
pacing, and lowers cardiac output.  This is of particular concern, as outcomes of CRT 
patients with AF are worse than for patients without AF, regardless of bi-ventricular (bi-
V) pacing percentage.41  However, patients in AF who undergo an atrioventricular node 
(AVN) ablation procedure have been shown to experience outcome rates similar to those 
patients in sinus rhythm, ostensibly mitigating the deleterious effects of AF.42  One 
editorial has even advocated that AVN ablations are a “fundamental step” in insuring the 
best results from CRT.69   
Heart rate variability (HRV), which is a measure of variability of the intrinsic atrial 
rhythm of the patient, has also been shown to affect outcomes, with lower HRV being 
associated with higher mortality.46  However, measurement of HRV is problematic when 
a patient experiences persistent AF or experiences atrial pacing from the device most of 
the time, as there are no clear P-waves to detect and measure atrial rhythm in the former 
   61 
 
case, and the measured atrial-atrial cycle length in the latter case is not physiologically 
meaningful as it is determined by the device, not the patient’s intrinsic rhythm.  
The objective of this study was to determine the relationship between the variables 
of bi-V pacing percentage, HRV, AF burden, and their interactions and all-cause patient 
mortality and HF-related hospitalization.  We hypothesized that higher bi-V pacing 
percentage was associated with lower rates of all-cause mortality, as well as lower HF-
related hospitalizations, after adjusting for significant clinical covariates, specifically 
including baseline AF burden, HRV, and AVN ablation status.  In addition, we expected 
that the association of bi-V pacing percentage with outcomes would be modified by AF 
burden, HRV, or AVN ablation status.   
4.3 Methods 
4.3.1 Study	Population	
Using similar procedures to those used in Manuscript 1 above, we analyzed the 
Medicare population with Medtronic CRT devices measuring AF burden and heart rate 
variability, implanted from January 2005 to April 2006, and with at least one CareLink® 
transmission by the time Medicare follow-up ended in December 2011.  A total of  2,625 
patients were matched between the Medicare data and the CareLink® registry in this 
analysis.  A pictorial representation of how these data were merged is shown in Figure 
14. 
4.3.2 Endpoint	Definition	
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As in Manuscript 1, time until first HF hospitalization in the Medicare dataset was 
determined by an inpatient admission with a primary ICD-9-CM diagnosis code of 428.x.  
For mortality endpoints, the available MedPAR data contained only all-cause mortality.   
4.3.3 Exposure	Definition	
The main exposure of interest was percentage of bi-V pacing, which was directly 
measured and reported daily in the CareLink® data.  The values of % bi-V pacing, HRV, 
and AF burden were determined at baseline by calculating the average of the first 30 days 
of device-reported daily values in the CareLink® database for each of these variables.  
We dichotomized the baseline bi-V pacing variable (Low/High), with a cutoff at 99% 
pacing, based on log-likelihood values of model results varying this cutoff value until the 
lowest log-likelihood value was obtained.  Heart rate variability measured by the device 
is the standard deviation of a 5-minute median atrial sensed interval (SDAAM) over a 24-
hour period, and the units are given in milliseconds. Since the SDAAM measurement is 
based on a patient’s intrinsic atrial cycle length, the CRT-D device does not store an 
HRV value for a given day if the percentage of time the device is pacing the atrium is 
greater than 80% of the 24-hour period, or if the patient experienced AF for more than 
80% of the time during that period.  We therefore created a “Missing” value for the HRV 
variable (presumably patients with >80% atrial pacing, atrial tachycardia (AT), or AF), 
and grouped the remaining patients into quartiles (<55.8ms, 55.8-67.9ms, 69.0-83.6ms, 
and >83.6ms).  Finally, AV node ablation status at baseline and during follow up, and 
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procedure date were determined based on a Current Procedure Terminology (CPT) code 
of 93650 in the Medicare data. 
Since the HRV measurement is not only tied to AF burden, but also to atrial 
pacing percentage, we additionally calculated and included a 30-day baseline atrial 
pacing percentage variable from available CareLink® data. 
4.3.4 Covariates	
Other variables available at the time of device implant in the Medicare registry that 
were considered in this analysis included patient age, duration of HF, LVEF, QRS duration, 
systolic blood pressure, diastolic blood pressure, heart rate, sex, NYHA class, presence of 
ischemic cardiomyopathy, bundle-branch block (BBB) morphology, prior coronary artery 
bypass graft (CABG), AF, anticoagulation therapy for AF, presence of ventricular 
tachycardia, prior sudden cardiac arrest event, diabetes mellitus, prior myocardial 
infarction, chronic kidney disease, end-stage renal disease, smoking status, and the 
prescription of beta-blockers, ACE-inhibitors or angiotensin receptor blockers, digoxin, 
diuretics, amiodarone, and/or warfarin. The diagnosis of chronic kidney disease (CKD) and 
end-stage renal disease (ESRD) was established based on administrative diagnosis codes 
from inpatient and outpatient encounters, available in CMS utilization files from the year 
the device was implanted. 
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4.3.5 Statistical	Analysis	
The associations of bi-V pacing, HRV, and AF burden with the outcomes of 
hospitalization and death were examined two ways.  We first analyzed the data via a Cox 
regression model using PROC PHREG in SAS, version 9.4 (SAS institute, Cary, NC) 
with all covariates fixed at their registry-reported baseline values determined, or based on 
their device-measured average value during the first 30 days after CRT implant.  We then 
ran an extended Cox regression model, adding the time-dependent AVN ablation 
covariate, with all other variables in the model fixed as before.  Both models specifically 
included the effects of bi-ventricular pacing, AF burden, and heart rate variability as well 
as the other covariates available in the Medicare ICD registry.   We also specifically 
looked for interactions between variables by adding separate interaction terms to the 
model between bi-V pacing and AF burden, bi-V pacing and HRV, AF burden and HRV 
and in the second analysis, AVN ablation status and bi-V pacing, ablation status and 
HRV, ablation status and AF burden in addition to the other terms listed above. The final 
set of covariates were selected by stepwise backwards selection, with the specific 
inclusion of the above-stated interactions, and were further evaluated qualitatively based 
on known effects of covariates on heart failure survival (e.g., those with diabetes mellitus 
are expected to experience poorer outcomes).   
Analyses for hospitalization endpoints were run both with cause-specific models, 
where all competing outcomes other than HF hospitalization (specifically, patient death) 
were censored, as well as competing risk (or subdistribution) models, where patients who 
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died were left in the denominator to estimate actual observable patient hospitalization 
rates.65 Since hospitalizations from patients with HMO/MCO coverage may be missed if 
they are not billed to Medicare, and are rather billed to the patients HMO/MCO instead,  
where HF-related hospitalization outcomes were examined we further created two 
additional models: one model adjusting for whether the patient had supplemental health 
maintenance organization (HMO)/ managed care organization (MCO) coverage, and 
another model excluding those patients with and HMO/MCO coverage, as reported in the 
Medicare data.   
4.4 Results 
Table 8 shows the subset of patients analyzed in this study compared to those in the 
Medicare dataset who were not examined (those without Medtronic devices).  Patients in 
the analysis cohort had statistically significantly greater LVEF, QRS interval, proportions 
of NYHA class I, II, and III patients, BBB morphology, ACE or ARB, and warfarin 
prescription.  They also had lower heart rate, lower proportions of ischemic 
cardiomyopathy, diabetes mellitus, prior myocardial infarction, chronic kidney disease 
(CKD), end-stage renal disease (ESRD), and amiodarone prescription than those who 
were not analyzed.  However, these differences were small and not expected to be of 
practical clinical significance. 
In this retrospective cohort study, we linked 2,625 patients between the Medtronic 
CareLink® database and the Medicare ICD Registry, representing approximately 34.2% 
of available Medicare patients with a Medtronic CRT device.  Over the median follow up 
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period of 6.4 years, we observed a mortality rate of 8.8 deaths per 100 person-years 
(1,186 deaths/13,676 person-years) and a HF-related hospitalization rate of 9.4 patients 
being hospitalized for the first time per 100 person-years (1,050 hospitalizations/11,207 
person-years).  We examined first HF-related hospitalizations only.  Slightly more than 
half of patients (51.7%) had bi-V pacing percentages over 99%, with a mean of 94.1% bi-
V pacing.  There were 1,949 patients with no device-measured AF during the first 30 
days after implant.  Of the remaining 646, the median device-measured AF burden was 
3.0%, with a bi-modal distribution towards either high or low values of AF burden as 
shown in Figure 15.  A total of 149 patients (5.7%) in our merged cohort underwent an 
AVN ablation procedure either prior to or during device implant (57 out of 149) or during 
their follow-up (92 out of 149).  In order to examine whether device-measured AF burden 
was representative of AF burden over time, we further examined whether their AF burden 
30 days prior to the ablation procedure was similar to their baseline AF burden 
measurement.  Of those who experienced an AVN ablation during follow-up, we had 
device data for 86 patients for the 30 days before the ablation procedure.  Those with 
clinician-diagnosed AF at the time of implant (that is, those with AF noted in the 
Medicare ICD Registry) had a 4.5 times higher odds of experiencing an AVN ablation 
(OR 4.5, 95%CI: 3.1-6.5) than those without clinician-diagnosed AF at implant, and 
Figure 16 shows the pairwise evolution of patients’ AF burden values from the first 30 
days after implant to the 30 days before an ablation procedure.  Only a modest, but still 
statistically significant, correlation was observed (Pearson’s r = 0.23, p-value=0.03). 
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Baseline Main Effects and Interactions – No Time-Dependent Covariates 
In the analysis that did not consider the time-dependent AVN ablation status, 
shown in Table 9, we found that patients with <99% baseline bi-V pacing experienced a 
28% higher mortality rate (HR 1.28, 95%CI: 1.14-1.45) and a 27% higher HF-related 
hospitalization rate (HR 1.27, 95%CI: 1.11-1.43) than those with ≥99% baseline bi-V 
pacing, after adjustment for baseline AF burden, baseline HRV quartile, ischemic 
cardiomyopathy, smoking status, age at implant, patient sex, diastolic blood pressure, 
prior coronary artery bypass graft (CABG) procedure, diabetes mellitus, and prescription 
of a diuretic, or ACE-inhibitor or ARB.  Further, those patients with <55.8ms baseline 
HRV (lowest quartile) had a 54% greater rate of mortality compared to those patients 
with >83.6ms baseline HRV (HR 1.54, 95%CI: 1.25-1.90).  We likewise found higher 
mortality rates among those patients in intermediate HRV quartiles (31% and 33% for 
quartiles 2 and 3 compared to quartile 4, respectively), but no greater hospitalization rates 
for these patients compared to those in the highest quartile.  Those with missing baseline 
HRV values due to high device-measured AF burden and/or atrial pacing percentages 
experienced a 38% higher mortality rate compared to those with >83.6ms baseline HRV 
(HR 1.38, 95%CI: 1.14-1.66) after adjustment for these same covariates.  Baseline AF 
burden was not associated with mortality, but there was a 15% to 17% increase in 
hospitalization rate, depending on whether HMO/MCO patients were included, and 
whether the model calculated the cause-specific or competing-risk hospitalization rates. 
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Baseline Main Effects and Interactions with Time-Varying AVN Ablation Status 
Table 10 lists the full results of the analysis including the time-varying AVN 
ablation status variable, where we found two separate interactions:  one between baseline 
bi-V pacing category and the presence of any device-measured AF at baseline, and 
another interaction between HRV quartile and AVN ablation status.  In the absence of 
any baseline device-measured AF, patients with bi-V pacing percentage <99% at baseline 
had a 33% higher mortality rate (HR 1.33,  95%CI: 1.16-1.52) and a 27% higher 
hospitalization rate (HR 1.27, 95%CI: 1.10-1.47) compared to those with ≥99% bi-V 
pacing after adjusting for AVN ablation status, baseline AF burden, HRV, ischemic 
cardiomyopathy, smoking status, patient age at implant, patient sex, diastolic blood 
pressure, prior CABG procedure, diabetes mellitus, as well as the prescription of a 
diuretic, ACE-inhibitor or ARB, and in the case of hospitalization outcomes, any 
HMO/MCO coverage.  There was no association observed for <99% bi-V pacing vs 
≥99% and mortality for patients with AF (HR 1.05, 95%CI: 0.83-1.23).  Consistently, 
there was little difference between the mortality rates for either bi-V pacing category 
among those patients with any device-measured AF at baseline (HR 1.31, 95% CI: 1.12-
1.54 for <99% bi-V pacing, and HR 1.26, 95% 0.99-1.59 for ≥99% bi-V pacing) 
compared to those with no AF and ≥99% bi-V pacing (p-value for interaction = 0.10).   
Further, in those patients without AVN ablations, lower HRV was associated with 
worse outcomes, where those with HRV values below 55.8 ms (lowest quartile, Q1) had 
a 63% greater mortality rate (HR 1.63, 95%CI: 1.31-2.02) and a 47% greater HF-related 
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hospitalization rate (HR 1.47, 95%CI: 1.18-1.83) compared to patients with HRV values 
above 83.6 ms (highest quartile, Q4).  These beneficial associations between HRV and 
mortality or HF-related hospitalization disappeared in patients who had undergone AVN 
ablations (p-value for interaction = 0.07).  Missing HRV values due to >80% baseline AF 
burden and/or atrial pacing percentage were associated with a 41% increased mortality 
rate (HR 1.41, 95%CI: 1.16-1.72) and a 40% increased rate of HF-related hospitalization 
(HR 1.40, 95%CI: 1.15-1.71) compared to those in the highest HRV quartile (>83.6ms). 
However, no association was found between HRV and HF-hospitalization for those with 
missing HRV values after AVN ablation.  AVN ablation itself was indicative of 260% 
higher mortality rates among those in the highest quartile of HRV values (HR 3.60, 
95%CI: 1.99-6.50), as well for those with missing HRV values.  However, as shown in 
Table 10, this effect was not seen for other HRV quartiles, nor was there a consistent 
effect on hospitalization rates, depending on whether patients with additional HMO/MCO 
coverage were excluded from the analysis, or whether the cause-specific HR or 
competing risks (subdistribution) HR was calculated.  Other interactions we explored, 
namely bi-V pacing and HRV, bi-V pacing and AVN ablation status, HRV and baseline 
AF burden, and baseline AF burden and AVN ablation status were not statistically 
significant. We also examined the effect of race in this analysis, but it was not found to 
be a significant predictor of either mortality or hospitalization and was therefore dropped 
from the models. 
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4.5 Discussion 
There is a complex relationship between biventricular pacing, AF, and HRV in the 
context of CRT.  CRT patients with AF pose a particular challenge, as AF interferes with 
the positive effects of bi-V pacing.  Those patients in our cohort with 99% or greater bi-V 
pacing experienced lower all-cause mortality and lower hospitalization rates than those 
with lower bi-V pacing, adding to the growing body of literature supporting that the 
closer to 100% bi-V pacing the better. Our 99% cutoff value is largely consistent with 
other studies that have examined bi-V pacing, which have separately reported 92% and 
98.7% as optimal bi-V pacing percentages.40,41 
Unusually, neither clinician-diagnosed AF, nor device-measured baseline AF 
burden appeared to be statistically significantly associated with study outcomes in any of 
our models, with the only significant AF-related variable being the time-dependent 
association of AVN ablation in interaction with other baseline variables.  The direction of 
this association was also unexpected in that AVN ablations were associated with 
increased mortality and HF-related hospitalization among those in the highest HRV 
quartile, or even those with missing baseline HRV values, indicating that they likely have 
high AF burden and/or atrial pacing percentages.  Figure 16 shows that the device-
recorded baseline AF burden measurement is not particularly representative of future AF 
burden among those with AVN ablations, with only a very modest correlation between 
the baseline measured value and the pre-ablation value (Pearson’s r=0.24).  The finding 
of higher mortality rates among AVN ablation recipients is therefore likely due to other 
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factors, including natural progression of their disease, which is not captured in the 
baseline AF burden metric alone.  We believe that the apparent detriment of AVN 
ablation shown in Table 10 is due to worsening patient health and disease progression 
necessitating the AVN ablation, which is not captured in either the baseline AF burden 
metric, the Medicare AF diagnosis, or the “missing” HRV value, rather than the ablation 
itself.  Previous studies examining the effect of AF after AVN ablation in CRT patients 
did not describe how the diagnosis of AF was determined to compare against our 
methodology.  Further, reasons for performing AVN ablations were not documented 
during follow-up, so we cannot truly know why an ablation procedure was performed.  
However, due to the nature of our Medicare cohort, AVN ablation practices in our study 
should be representative of real-world circumstances, not guided by any formal clinical 
study protocol. 
The observed interaction between baseline HRV and AVN ablation suggests that 
upon ablation, a patient loses the benefit bestowed by intrinsic atrial rate control.  
Consistent with previous literature, higher intrinsic atrial rate variability is associated 
with lower overall mortality, as shown in Table 10.  Once an ablation occurs, there is no 
communication between atria and ventricles, rendering the actual atrial rate moot, and 
forcing the device to pace the ventricles 100% of the time.  Whether the loss of this HRV 
benefit is outweighed by the prevention of ventricular tachycardia and/or arrhythmia 
must be considered by the physician when determining whether to perform an AVN 
ablation. 
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Our data-matching scheme linked 2,625 patients between the Medicare ICD 
registry and the Medtronic CareLink® network for this analysis.  As noted in Manuscript 
1 above, at the time the Medicare Registry was maintained an estimated 39% of 
Medtronic CRT patients were enrolled in the CareLink® network (Medtronic data on file, 
2016), and therefore expect approximately 2,990 of Medicare registry patients to be 
found in both data sources.  Therefore our 34.2% (2,625 patients) match between these 
two registries seems reasonable. 
The limitations of this study include the fact that CRT pacing percentages have 
been shown to overestimate actual effective pacing percentage.  It has been observed that 
while the CRT-D device reports >90% bi-ventricular pacing, up to 40% of overall paced 
beats can be fusion and pseudo-fusion beats.35  However, due to this overreporting of bi-
V pacing percentage from the device we would expect the measures of association 
calculated in this study to underestimate the true effect of high proportions of bi-V 
pacing.  We are also limited by the assumption that baseline HRV, bi-V pacing, and AF 
burden are indicative of patient characteristics throughout the follow-up period.  As we 
have shown, this is somewhat problematic for the AF burden variable, as our results 
pertaining to AF differ from previous studies. 
In conclusion, baseline bi-ventricular pacing percentages ≥99% were associated 
with both lower mortality and HF-related hospitalization outcomes in a cohort of 
Medicare ICD patients after adjusting for key covariates with over 6 years of follow-up.  
An interaction was noted between missing HRV data, representing high percentages of 
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AF and/or atrial pacing, in Medtronic’s CareLink® data and bi-V pacing, whereby high 
bi-ventricular pacing was associated with better outcomes in the presence of HRV data 
(low AF burden and low atrial pacing percentage), but no benefit if HRV data were 
missing. 
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4.6 Tables and Figures 
Figure 14. – Manuscript 2 Cohort Selection and Data Merging Scheme 
 
  
Medtronic CareLink® Registry 
Medtronic CRT-D Devices 
n= 7,670 
Data joined on Implant Date (±2 days), Patient Age (±2 years), Patient Sex, Device Model, 
and de-identified (3-digit) ZIP Code 
CRT-D Devices Implanted between 
Jan 1, 2005 and Apr 30, 2006 
n=21,797 
All Medicare Registry CRT 
Devices  
n=14,935 
Non-MDT 
Devices 
n= 5,957 
Final Medtronic CRT-D CareLink® 
Devices with Medicare 
Registry/Outcomes Cohort 
n=2,625 
Medtronic CRT-D Devices 
n= 8,978 
Outside 
Guidelines 
n= 1,308 
Unmatched 
(device not 
enrolled in 
CareLink®) 
n=5,045 
Unmatched 
(do not have 
Medicare) 
n=19,172 
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Table 8. – Baseline Demographic and Clinical Characteristics for Medicare CRT Patients 
by Analysis Cohort 
 All Medicare CRT 
Patients(n=14,935) 
Analysis Cohort 
(n=2,625) 
Non- Analyzed 
Cohort (n=12,310) 
p-value* 
Age, mean ±SD, y 73.0±10.5 73.1±8.0 73.0 ± 10.9 0.45 
Duration HF, mean ±SD, 
months 
24.7±25.4 25.5±25.9 24.5±25.3 0.08 
LVEF, mean ±SD, % 23.1±6.3 23.5±6.3 23.0±6.4 <0.001 
QRS duration, mean 
±SD, ms 
156.8±24.9 158.7±24.8 156.4±24.9 <0.001 
SBP, mean ±SD, mm Hg 126.5±22.4 126.3±21.4 126.5±22.6 0.67 
DBP, mean ±SD, mm Hg 70.2±13.7 70.3±12.4 70.1±14.0 0.56 
Heart rate, mean ±SD, 
bpm 
72.0±18.0 71.2±14.4 72.2±18.7 0.003 
Sex, n(%)     
Female 27.3 26.7 27.4  
Male 72.7 73.3 72.6 0.44 
NYHA class, (%)     
I 1.2 1.3 1.2  
II 11.0 11.3 10.9  
III 74.2 76.8 73.6 <0.001 
IV 13.6 10.6 14.3  
Ischemic CM, (%) 69.2 64.8 70.1 <0.001 
Prior CABG, (%)     
BBB Morphology, (%)     
LBBB 69.3 71.2 68.9  
RBBB 11.0 9.7 11.2 0.03 
Other IVCD 19.8 19.1 19.8  
Atrial fibrillation, (%) 34.7 35.7 34.5 0.24 
Ventricular tachycardia, 
(%) 
19.6 18.4 19.8 0.10 
Sudden cardiac arrest, 
(%) 
1.7 1.5 1.8 0.39 
Diabetes mellitus, (%) 35.7 33.9 36.1 0.04 
Prior MI, (%) 50.9 49.0 51.3 0.03 
Chronic Kidney Disease, 
(%) 
32.0 25.8 33.3 <0.001 
End-Stage Renal 
Disease, (%) 
3.1 1.6 3.4 <0.001 
Smoker Status, (%)     
Never 42.3 42.5 42.2  
Former 48.6 49.4 48.5 0.17 
Current 9.1 8.2 9.3  
Medications, (%)     
b-blocker 78.9 80.2 78.6 0.07 
ACEI or ARB 74.3 77.4 73.6 <0.001 
Digoxin 41.7 41.5 41.8 0.83 
Diuretic 78.7 79.3 78.5 0.39 
Amiodarone 13.6 11.9 13.9 0.004 
Warfarin 31.8 34.3 31.3 0.003 
*p-value comparing analyzed cohort to non-Analyzed cohort. 
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Table 9. – Hazard Ratios of Mortality or First HF Hospitalization for Baseline Bi-V Pacing, 
HRV, and AF Burden.  Models include all covariates in the table simultaneously. 
 
Hazard Ratio 
for Patient 
Mortality 
Cause-specific Hazard Ratio for 
Heart Failure-related 
Hospitalization 
Subdistribution Hazard Ratio for 
Heart Failure-related 
Hospitalization 
Including 
Medicare 
HMO/MCO 
Patients 
Excluding 
Medicare 
HMO/MCO 
Patients 
Including 
Medicare 
HMO/MCO 
Patients 
Excluding 
Medicare 
HMO/MCO 
Patients 
# of events 
1,186 1,050 980 
1,050 (513 
competing) 
980 (444 
competing) 
Follow up time 
(person-years) 
13,676 11,207 10,029 11,207 10,029 
Baseline Bi-V 
pacing (<99% vs 
≥99%) 
1.28 (1.14-1.45) 1.27 (1.11-1.43) 1.23 (1.09-1.41) 1.22 (1.08-1.39) 1.20 (1.05-1.37) 
Baseline AF 
(Any AF vs No 
AF) 
1.08 (0.94-1.24) 1.17 (1.02-1.35) 1.17 (1.01-1.36) 1.16 (1.00-1.34) 1.15 (1.00-1.34) 
Baseline HRV  
Q1 vs Q4 
Q2 vs Q4 
Q3 vs Q4 
Missing vs Q4 
 
1.54 (1.25-1.90) 
1.31 (1.06-1.63) 
1.33 (1.07-1.65) 
1.38 (1.14-1.66) 
 
1.45 (1.16-1.79) 
1.10 (0.88-1.38) 
1.00 (0.79-1.25) 
1.38 (1.14-1.68) 
 
1.40 (1.12-1.76) 
1.09 (0.87-1.38) 
0.98 (0.77-1.24) 
1.33 (1.09-1.63) 
 
1.37 (1.10-1.71) 
1.07 (0.86-1.34) 
0.95 (0.76-1.19) 
1.34 (1.11-1.62) 
 
1.33 (1.06-1.67) 
1.06 (0.85-1.33) 
0.94 (0.74-1.19) 
1.29 (1.06-1.57) 
Ischemic 
Cardiomyopathy 
(Y vs N) 
1.22 (1.04-1.41) 1.14 (0.96-1.33) 1.10 (0.93-1.30) 1.10 (0.93-1.28) 1.08 (0.91-1.27) 
Smoking Status 
Current vs Never 
Former vs Never 
 
1.68 (1.36-2.09) 
1.17 (1.03-1.32) 
 
1.44 (1.14-1.82) 
1.17 (1.03-1.34) 
 
1.36 (1.07-1.74) 
1.13 (0.99-1.30) 
 
1.33 (1.05-1.69) 
1.15 (1.01-1.31) 
 
1.27 (0.99-1.63) 
1.11 (0.97-1.28) 
Age at Implant 
(per 10 yrs) 
1.42 (1.30-1.54) 1.10 (1.01-1.20) 1.11 (1.02-1.22) 1.06 (0.97-1.16) 1.08 (0.98-1.18) 
Patient Sex 
(female) 
0.75 (0.64-0.87) 0.95 (0.82-1.11) 0.91 (0.78-1.07) 0.98 (0.84-1.14) 0.93 (0.80-1.10) 
Diastolic Blood 
Pressure (per 
10mm Hg) 
0.91 (0.87-0.96) 0.93 (0.89-0.98) 0.93 (0.89-0.98) 0.94 (0.89-0.99) 0.94 (0.89-0.99) 
Prior CABG (Y 
vs N) 
1.15 (1.00-1.32) 1.15 (1.00-1.33) 1.18 (1.01-1.37) 1.12 (0.97-1.30) 1.14 (0.98-1.33) 
Diabetes Mellitus 
(Y vs N) 
1.33 (1.18-1.49) 1.32 (0.67-0.86) 1.30 (1.14-1.47) 1.25 (1.11-1.43) 1.23 (1.08-1.41) 
Diuretic (Y vs N) 1.27 (1.09-1.47) 1.52 (1.28-1.79) 1.54 (1.28-1.82) 1.49 (1.27-1.79) 1.52 (1.28-1.82) 
ACE or ARB (Y 
vs N) 
0.78 (0.68-0.88) 0.77 (0.67-0.88) 0.76 (0.66-0.88) 0.80 (0.69-0.92) 0.79 (0.68-0.92) 
Any HMO/MCO 
Coverage (Y vs 
N) 
N/A 0.60 (0.47-0.76) N/A 0.57 (0.45-0.72) N/A 
 
  
   77 
 
Table 10. – Adjusted Hazard Ratios for AVN Ablation Status, Baseline Bi-V pacing, AF 
burden, HRV, and Their Interactions  
 Hazard Ratio for 
Patient Mortality 
Cause-specific Hazard Ratio for 
Heart Failure-related 
Hospitalization 
Subdistribution Hazard Ratio for 
Heart Failure-related 
Hospitalization 
Including 
Medicare 
HMO/MCO 
Patients 
Excluding 
Medicare 
HMO/MCO 
Patients 
Including 
Medicare 
HMO/MCO 
Patients 
Excluding 
Medicare 
HMO/MCO 
Patients 
# of events 1,186 1,050 980 1,050 (513 
competing) 
980 (444 
competing) 
Follow up time (person-
years) 
13,676 11,207 10,029 11,207 10,029 
 
Adjusted* Associations of Baseline Bi-V pacing (>99% vs <99%) by Baseline AF Status (Any vs None) 
<99% bi-V Pacing/Any AF 
<99% bi-V Pacing/No AF 
 
≥99% bi-V Pacing/Any AF 
≥99% bi-V Pacing/No AF 
1.31 (1.12-1.54) 
1.33 (1.16-1.52) 
 
1.26 (0.99-1.59) 
1 (reference) 
1.47 (1.24-1.73) 
1.27 (1.10-1.47) 
 
1.20 (0.94-1.55) 
1 (reference) 
1.45 (1.21-1.72) 
1.23 (1.06-1.43) 
 
1.16 (0.90-1.51) 
1 (reference) 
1.42 (1.20-1.68) 
1.23 (1.06-1.42) 
 
1.15 (0.89-1.49) 
1 (reference) 
1.40 (1.17-1.65) 
1.19 (1.02-1.38) 
 
1.11 (0.85-1.45) 
1 (reference) 
 
Adjusted* Associations of AVN Ablation Status (Y vs N) by Baseline HRV Quartile 
Missing HRV/ Ablation 
Q1 HRV/ Ablation 
Q2 HRV/ Ablation 
Q3 HRV/ Ablation 
Q4 HRV/ Ablation 
 
Missing HRV/ No Ablation 
Q1 HRV/ No Ablation 
Q2 HRV/ No Ablation 
Q3 HRV/ No Ablation 
Q4 HRV/ No Ablation 
2.04 (1.47-2.85) 
1.88 (0.95-3.69) 
1.07 (0.58-5.76) 
2.30 (1.07-4.95) 
3.60 (1.99-6.50) 
 
1.41 (1.16-1.72) 
1.63 (1.31-2.02) 
1.39 (1.11-1.73) 
1.39 (1.11-1.73) 
1 (reference) 
1.39 (0.94-2.06) 
1.36 (0.43-4.30) 
1.11 (0.27-4.52) 
2.18 (0.89-5.35) 
2.13 (0.79-5.78) 
 
1.40 (1.15-1.71) 
1.47 (1.18-1.83) 
1.12 (0.89-1.40) 
0.99 (0.78-1.25) 
1 (reference) 
1.35 (0.90-2.01) 
1.35 (0.43-4.24) 
1.10 (0.27-4.48) 
2.23 (0.91-5.48) 
2.31(0.85-6.26) 
 
1.36 (1.11-1.66) 
1.43 (1.14-1.79) 
1.11 (0.88-1.40) 
0.97 (0.76-1.24) 
1 (reference) 
1.22 (0.79-1.87) 
1.60 (0.42-6.06) 
1.19 (0.30-4.79) 
2.31 (0.86-6.17) 
2.10 (0.99-4.47) 
 
1.37 (1.13-1.67) 
1.39 (1.12-1.73) 
1.09 (0.87-1.36) 
0.94 (0.75-1.19) 
1 (reference) 
1.18 (0.77-1.83) 
1.58 (0.42-5.97) 
1.18 (0.29-4.72) 
2.34 (0.88-6.24) 
2.42 (1.25-4.72) 
 
1.33 (1.09-1.62) 
1.35 (1.08-1.70) 
1.08 (0.86-1.36) 
0.93 (0.73-1.19) 
1 (reference) 
* Adjusted for patient age at implant, sex, ischemic cardiomyopathy, diastolic blood pressure, 
prior CABG procedure, smoking status, diabetes mellitus, diuretic, ACE or ARB prescription, and 
for hospitalization events, any HMO/MCO coverage (Y/N). 
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Figure 15. – Distribution of Baseline AF Burden (% of time patient is in AF) among 
Patients with Any AF 
 
*Baseline_AF_Burden = proportion of time the patient experiences atrial tachycardia and/or atrial 
fibrillation (AT/AF) 
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Figure 16. – Comparison between Baseline AF Burden and AF Burden 30 days Prior to 
AVN Ablation (n=86, AVN Ablation patients only) 
	
* Lines connect measurements within an individual patient 
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5 Manuscript	3	–	Use	of	Implantable	Device	Heart	Failure	
Diagnostics	to	Predict	30-day	HF-Rehospitalization	
5.1 Overview 
Objective: To improve upon the existing 30-day heart failure hospital readmission 
prediction model of Small, et al., by the addition of baseline clinical information found in 
the Medicare registry.  
Background: With the advent of the 30-day rehospitalization penalty from the Centers 
for Medicare and Medicaid Services (CMS), it is imperative to determine which patients 
may be at risk of imminent rehospitalization.  In addition to the poorer outcomes for 
patients, there is the potential for reduced Medicare payments to providers if their facility 
experiences higher rates of 30-day rehospitalization.  We look to improve existing risk 
stratification models, which use device-measured data on the day of discharge for HF-
hospitalization, by adding patient baseline clinical information.  Methods: The Cox 
regression model of Small, et al. (daily impedance >8Ω below reference impedance, AF 
>6 hrs in previous 24, night heart rate >80 bpm, CRT pacing <90%) was applied to a 
cohort of Medicare ICD Registry patients with at least one HF-related hospitalization and 
at least 30 days of follow-up information available in both CareLink® and Medicare 
claims.   Further, a bootstrap variable selection process utilizing both derivation and 
validation cohorts was performed including the variables of the Small, et al. model.  This 
model then had remaining non-significant variables removed. Results: Of 607 index 
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hospitalizations in our cohort of 1,563 patients, 107 experienced a rehospitalization 
within 30 days.  Those who met one of the device-measured criteria at discharge, which 
were set forth in the model developed by Small, et al., had a 70% higher rate of 30-day 
rehospitalization compared to those who met none of the criteria (HR 1.7, 95% CI: 1.1-
2.7).  Additional device-measured criteria that were met did not further increase risk 
identification significantly (2+ criteria vs none HR: 1.8, 95%CI 1.1-2.9).  The bootstrap 
selection model indicated that the impedance criterion of Small, et al., was the only 
criterion of primary importance, as well as the registry variables of diuretic prescription, 
chronic kidney disease, NYHA class at implant, male sex, prior coronary artery bypass 
graft (CABG) procedure, and longer duration of heart failure at the time of the index 
hospitalization.  The AUC from our final model in our validation cohort was 0.76 
(95%CI: 0.71-0.81), and the model was well calibrated (Hosmer-Lemeshow χ² = 11.96, 
p-value=0.15).  
Conclusion:  We have derived a model based on device-measured and clinical variables 
that predicts risk of 30-day HF-related hospitalization.  Variables associated with kidney 
dysfunction at the time of discharge from a HF-related index hospitalization were most 
strongly predictive of rehospitalization within 30-days. 
 
5.2 Introduction 
Frequent hospitalizations place considerable suffering on patients living with HF, 
as well as burden on clinicians managing these patients.70  Many HF patients experience 
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severe, acute episodes of symptoms including fatigue, dyspnea, edema, sudden weight 
gain, and chest pain, which require immediate treatment and/or hospitalization.  While 
more HF-related hospitalizations themselves have been associated with poorer 
outcomes71, there is also an economic burden to the healthcare system in treating these 
patients. As of 2012, these costs stood at $20.9 billion in direct treatment costs, and a 
further $9.8 billion in indirect, or lost productivity, costs.2  In an effort to reduce the 
frequency of rehospitalizations, the Centers for Medicare and Medicaid Services (CMS) 
instituted their Hospital Readmissions Reduction Program (HRRP) in 2012, which 
financially penalizes providers who have excessive 30-day rehospitalization rates (see 
https://www.cms.gov/medicare/medicare-fee-for-service-
payment/acuteinpatientpps/readmissions-reduction-program.html for more information).  
Therefore, development of interventions or criteria that can identify patients at higher risk 
of 30-day readmission is of critical importance, such that better interventions or more 
frequent monitoring strategies can be employed. 
Small, et al., have developed a model for predicting HF readmission based on four 
CRT device-measured criteria on the day of an index HF-hospitalization discharge.57  
These parameters are based on the daily measurement of intrathoracic impedance (>8 Ω 
below the reference impedance), atrial fibrillation burden (>6 hrs of the past 24), night 
heart rate (>80 bpm), and CRT pacing percentage (<90% pacing).  They reported that 
those patients who met one of these four criteria on the day of discharge were 
hospitalized within 30 days at a rate 2.4 times higher than those patients who met none of 
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these criteria (HR 2.4, 95% CI: 1.1-5.3).  Further, those who met two or more criteria 
were hospitalized at a rate 4.4 times higher than those who met none of the criteria (HR 
4.4, 95%CI: 1.6-12.0).  This study suffers from the small number of events 
available(n=36), and the fact that other clinical covariates which may be associated with 
30-day readmission were not included in the model.  It further was composed of patients 
from four different clinical studies with differing inclusion and exclusion criteria, as well 
as case study files, potentially introducing selection bias in the cohort.  Therefore, 
predictive models developed in larger samples that consider more extensive clinical 
information and use standardized definitions of clinical variables are needed. 
We hypothesized that the 30-day HF-rehospitalization model developed by Small, 
et al., can be improved upon by the inclusion of one or more available clinical covariates 
as determined by significance testing, AUC (area under the curve) improvement, net 
reclassification improvement (NRI), or integrated discrimination improvement (IDI) 
methods. 
5.3 Methods 
5.3.1 Study	Population	
Patients who have an OptiVol®-enabled Medtronic CRT-D device implanted from 
January 2005 to April 2006 with at least one CareLink® transmission and at least one 
HF-related hospitalization event before Medicare follow-up ended in December 2011 
were matched between the Medicare and CareLink® datasets.  We excluded those 
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patients with any HMO/MCO coverage as indicated in the Medicare database since we 
are specifically looking at hospitalization risk, which may be significantly underestimated 
in these patients. 
5.3.2 Endpoint	Definition	
A primary ICD-9-CM diagnosis code of 428.x within 30 days of an index 
hospitalization constituted a 30-day rehospitalization event.  Per the CMS guidelines on 
rehospitalization, any heart failure-related hospitalization event during the follow-up 
period classified by a primary ICD-9-CM diagnosis code of 428.x for a given patient 
qualified as an index hospitalization if there were 30 days of device monitoring 
information available following discharge.  Thus, a single patient may have several index 
hospitalization events, and further, any given rehospitalization event may also count as an 
index event for the next 30-day interval. 
 
5.3.3 Exposure	Definition	
Data from the Medtronic CareLink® network from CRT-D devices implanted in 
the Jan 2005 to Apr 2006 timeframe were queried to determine the values of daily 
impedance, reference impedance, time in AT/AF, night heart rate, and percent bi-
ventricular pacing on the day of discharge from an index hospitalization.  The criteria of 
Small, et al., (daily impedance >8Ω below reference impedance, AF burden >6 hours, 
CRT pacing <90%, night heart rate >80 bpm) were then applied and coded as indicator 
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variables for use in modeling outcomes.  As per Small’s methodology, if device-
measured data were missing for a specific diagnostic criterion on the day of discharge, it 
was considered that that diagnostic criterion was not met. 
5.3.4 Covariates	
We examined all the available variables in the Medicare ICD registry at the time 
of device implant, including patient sex, bundle-branch block (BBB) morphology, 
cardiomyopathy origin (ischemic Y/N), left-ventricular ejection fraction (LVEF), systolic 
blood pressure (SBP), diastolic blood pressure (DBP), diabetes mellitus, smoking status, 
chronic kidney disease (CKD), end-stage renal disease (ESRD), and the prescription of 
digoxin, beta-blockers, diuretic, ACE inhibitor, ARB, amiodarone, or warfarin.   
Rather than use the baseline measures of patient age at implant, and duration of 
HF at implant, we also calculated patient age and duration of HF at the time of the index 
hospitalization and used those measures in the statistical analysis instead. 
5.3.5 Statistical	Analysis	
For the purposes of directly comparing our model to the original model published 
by Small, et al., we first performed a proportional hazards regression using PROC 
PHREG in SAS v9.4 (Cary, NC) using the indicator variables of intrathoracic impedance, 
AF burden, CRT pacing percentage, and night heart rate based on the criteria set forth by 
Small, et al., to calculate hazard ratios of a 30-day readmission event for those patients 
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who met no criteria versus those who met one criterion, and those who met no criteria 
versus those who met two or more criteria. 
To improve upon this model, we employed a Monte-Carlo (or bootstrap) approach 
of identifying predictors which were associated with a 30-day HF-rehospitalization 
event.72  The method involves splitting our cohort into derivation and validation subsets.  
For the purposes of this analysis, we randomly selected two-thirds of our cohort to derive 
the model, and held the other third for subsequent validation of the model. We then used 
PROC MULTTEST in SAS v9.4 to generate 1,000 datasets with the same number of 
observations as the original dataset, randomly selecting patients for each dataset from our 
derivation cohort with replacement.  As our main interest is specifically whether 30-day 
rehospitalization events occur, and not other time periods, we shifted our analysis to a 
logistic regression model using PROC LOGISTIC in SAS using stepwise backwards 
selection on each of these 1,000 datasets using a p-value threshold of 0.05 to remain in 
the model.  We initially forced the backwards selection process to include the four 
original indicator variables from the Small model, so that we could compare any potential 
model improvement directly with that model.  Any variable selected in more than 60% of 
the 1,000 model iterations was then included in our final model.  We then removed any 
remaining non-significant variables from the model, and the final list of parameters was 
then applied to the remaining validation portion of our cohort. 
We formally evaluated improvement to the Small model by examining the change 
in AUC, NRI, and IDI described by Pencina, et al.73,74  Reliance on statistics such as 
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AUC often requires new predictive variables to have enormous effect sizes to provide 
improvement of the model.75,76  However, by also examining NRI and IDI measures, they 
offer insight into the percentage improvement of correctly classifying those patients with 
events by including another predictor, as well as the changes in sensitivity with the new 
predictor, given a fixed specificity.  To avoid the dilemma of defining meaningful risk 
categories for NRI calculation, a category-free, or continuous NRI method was employed 
to calculate NRI, and any change upward or downward in probability of a 
rehospitalization event for a given patient between models was counted as such.74  Model 
calibration was assessed through the Hosmer-Lemeshow χ2 statistic. 
 
5.4 Results 
A total of 607 index hospitalizations were observed in our cohort of 1,563 patients 
from Manuscript 1 over a mean follow up of 6.3 years (297 patients experienced a single 
index hospitalization, 69 experienced two, and 45 more than 2).  Another hospitalization 
event occurred within 30 days after 17.6% of index hospitalizations (107 30-day 
rehospitalizations/607 index hospitalizations).  Patient characteristics of those events with 
and without 30-day rehospitalizations are shown in Table 11.  Those who did not 
experience a HF-related hospitalization event differed from those who did in that they 
were younger, had HF for a shorter duration before implant, lower LVEF, lower SBP and 
DBP, less likely to be diagnosed with CKD at baseline, more likely to be prescribed 
digoxin, warfarin, and diuretics, and also had a different distribution of NYHA class at 
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baseline.  These observed differences in these parameters were all formally tested for 
statistical significance in the modelling process, described above. 
 
Comparison to Proportional Hazards Model of Small, et al. 
A Kaplan-Meier plot of the present analysis based on the model published by 
Small, et al., containing only the four device-measured criteria is shown in Figure 17.  
The results from the proportional hazards regression indicated that those patients who 
met one criterion had a rehospitalization rate 1.7 times higher than those who met none of 
the four device-measured criteria in the model (HR: 1.7, 95%CI: 1.1-2.7).  Further, those 
who met two or more criteria had a rehospitalization rate 1.8 times higher than those who 
met no criteria (HR: 1.8, 95%CI: 1.1-2.9).  However, there was no significant difference 
between those who met a single criterion versus those who met two or more (HR 1.0, 
95%CI: 0.6-1.7).  Hazard ratios of the individual criteria from the Small model were also 
calculated and compared with the associations observed in the present study, as shown in 
Table 12.  Only the impedance criterion was found to be statistically significant in our 
cohort (HR 3.3, 95% CI: 2.0-5.8). 
 
Improvement of Small, et al., Model via Inclusion of Clinical Covariates in Logistic 
Regression Model Setting 
The results of our model-building process are summarized in Table 13.  Our 
derivation cohort (n=418) was run through the bootstrap parameter selection process, 
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where the parameters of diuretic prescription (selected in 91.3% of bootstrap models), 
diagnosis of CKD (89.5%), NYHA HF class (82.8%), patient sex (77.2%), prior coronary 
artery bypass graft (CABG) procedure (68.7%), and duration of HF at the time of the 
index hospitalization (62.9%) were stepwise backwards-selected by more than 60% of the 
bootstrap model datasets for inclusion into the model.  Parameters selected in less than 
60% of the bootstrap model datasets did not reach standard statistical significance criteria 
in either the derivation cohort, and we therefore stopped including parameters below the 
60% cutoff.  We also included the original four device-measured indicator variables in 
the model for a direct comparison with the Small model.  It should be noted that only the 
impedance criterion of the original four device-measured variables was found to be 
statistically significant in this analysis.  We then applied the bootstrap-selected set of 
parameters to our validation cohort (n=189).  However, in the validation cohort, the only 
additional clinical variables which were statistically significant were CKD diagnosis and 
duration of HF at the time of the index hospitalization, and diuretic prescription, patient 
sex, NYHA class, and prior CABG procedure were no longer significant.  
Model calibration was evaluated via the Hosmer-Lemeshow χ² statistic.  None of 
the models showed significant lack of fit, with χ² values ranging from 0.89 to 11.96 
depending on the exact cohort and model parameters in question.  Figure 18 shows the 
Hosmer-Lemeshow plot of expected probabilities of failure versus observed for the 
bootstrap-selected model based on the validation cohort, as well as the full cohort. 
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Also shown in Table 13, the calculated AUC for the logistic model in the validation 
cohort (n=189) including only the heart rate, daily impedance, AF burden, ventricular 
pacing, and night heart rate indicator variable criteria – the de facto Small, et al., model – 
was 0.61 (95%CI: 0.51, 0.71).  Including baseline diuretic prescription, CKD diagnosis, 
patient sex, CABG procedure prior to device implant, NYHA class, and duration of HF at 
the time of the index hospitalization in this same cohort (n=189) increased the AUC 
metric to between 0.73 and 0.76, depending on the analysis done, and the exact variable 
set included.  This improvement in AUC was significant across all the various models 
and sets of parameters examined. 
Further, the net reclassification improvement (NRI) was 0.76 (95%CI: 0.41-1.10) 
when comparing the model with the full bootstrap-selected set of parameters to the initial 
four device-measured criteria model used by Small, et al, with 31% of 30-day 
rehospitalizations being correctly reclassified from non-events to events, and 44% of non-
events being correctly reclassified as non-events from events.  The absolute integrated 
discrimination improvement (IDI) was 0.129(95% CI: 0.066-0.193), and the relative IDI 
was 2.24.  Removal of parameters which were not statistically significant reduced the 
AUC to 0.73 (95%CI: 0.63-0.83). 
We then categorized patients in our full cohort (n=607) into tertiles of risk, based 
on the predicted probability of a HF-related hospitalization within 30 days as predicted 
by the reduced bootstrap logistic regression model (low risk < 9.1%, average risk=9.1-
18.2%, and high risk >18.2%).  A Kaplan-Meier plot showing the survival of the three 
   91 
 
risk categories is shown in Figure 19.  All pairwise log-rank comparisons between risk 
categories (Low vs. Average, Low vs. High, Average vs. High) were statistically 
significant (p-values = 0.0003, <0.0001, and <0.0001, respectively).  
 
5.5 Discussion 
Our proportion of HF-hospitalization events (607 total HF-hospitalizations/1,563 
patients) was higher than that of Small, et al., (265 total HF-hospitalizations/1,562 
patients) even though our initial cohort is nearly identical in size.  We believe this is due 
to the long-term follow-up of our sample.  Even though the hospitalization rate we 
observed was lower than in the study by Small, et al., (the HF-hospitalization rate in the 
present study was 0.062 HF-hospitalizations per person-year, while Small observed an 
event rate of approximately 0.166 HF-hospitalizations per person-year), the average 
follow-up of the Small study was just over one year, while the present study is 6.3 years, 
allowing for more hospitalizations to occur during follow-up. The proportions of 
observed 30-day rehospitalizations between our study (17.6%) and theirs (16.6%) were 
not significantly different (p-value=0.74). 
As shown in Figure 17, our model was similar to the previously published model in 
that if any single criterion of the model was met, it was associated with an increased 
rehospitalization risk, but that any additional criteria which were met did not significantly 
increase risk further.  Of the four device-measured criteria, the most influential one was 
the impedance criterion. 
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The addition of the clinical covariates improved the predictive performance of our 
model significantly, as indicated not only by observed increases in AUC, but also in NRI 
and absolute and relative IDI measures.  While dependent on the actual AUC value, 
literature suggests that values of NRI greater than 0.60 indicate strong model 
improvement from the addition of these new variables.77,78  Further, our absolute IDI 
value shows that we increased the difference between average predicted probabilities for 
events and non-events by 12.9%.  Putting this on a relative scale, the observed relative 
IDI value indicates that we increased this difference in mean predicted probabilities of 
events and non-events by 224%, a large improvement.  Given the smaller sample size in 
our validation cohort, it is not surprising that some variables lost significance; rather, 
examining the AUC between the derivation and validation cohorts (0.78 and 0.76, 
respectively) indicates that the model in our validation cohort was still strong in 
predicting outcomes relative to the derivation cohort.  Further, our Hosmer-Lemeshow 
statistics for the derivation and validation cohorts were 9.65 (p-value=0.29) and 11.96 (p-
value=0.15), respectively, indicating no gross lack-of-fit. 
Reducing the model further in our validation cohort by removing parameters which 
were not statistically significant resulted in a non-significant reduction in AUC (p-
value=0.26).  However, reductions in both NRI and IDI measures comparing the reduced 
model to the full bootstrap model in the validation cohort indicated significant reductions 
in model discrimination, and we therefore left all of the terms selected in by the bootstrap 
process in the derivation sample in the model. 
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The most robust measures from model to model that predicted 30-day HF-related 
rehospitalization were associated with kidney function, namely: the prescription of a 
diuretic, intrathoracic impedance criterion (daily impedance more than 8Ω below the 
reference impedance), and diagnosis of CKD, indicating the critical role that kidney 
function plays in the rehospitalization risk of heart failure patients.  These factors show 
the potential to develop monitoring or interventional strategies guided by these factors to 
reduce 30-day rehospitalizations in CRT patients. 
While the addition of baseline clinical measures significantly improved the 
previous model, it should be noted that these variables were qualitative in nature, and 
were not updated over the follow-up period.  Specifically, we do not know diuretic 
dosage, for example, or if a patient was still prescribed a diuretic at the time of discharge 
from the index hospitalization.  We further lacked quantitative measures of kidney 
function, such as serum creatinine, glomerular filtration rate (GFR), and blood urea 
nitrogen (BUN), which may provide additional criteria or risk stratification refinement or 
a basis upon which to develop interventions.  Further study is warranted to determine 
whether the device-measured intrathoracic impedance criterion provides incremental 
predictive value over and above these other quantitative measures of kidney function. 
 We did not consider patient death to be a competing risk in this analysis, as the 
30-day time frame for patient mortality to compete with an index hospitalization is very 
short, and is not expected to meaningfully affect observed associations since the observed 
mortality rate in our initial cohort is 0.007 deaths per month (705 deaths/ 96,432 person-
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months). We also did not reevaluate the threshold value for meeting the impedance 
criterion at hospital discharge (daily impedance value >8Ω below reference impedance), 
as we desired a direct comparison with previous literature. 
In addition, our treatment of multiple hospitalizations from a patient did not 
consider that each index event might be correlated with prior index hospitalization.  That 
is, the probability of a rehospitalization within a 30-day interval might depend on prior 
hospitalizations a patient experienced.  Future work in this area could calculate NRI and 
IDI accounting for the within-patient correlation of hospitalization, and determine 95% 
confidence intervals via a bootstrap methodology. 
 In summary, we have derived a model based on device-measured and clinical 
parameters on the day of discharge for a HF-related hospitalization which predicts risk of 
rehospitalization within 30 days.  We have shown this model to be an improvement over 
an existing model, with better discrimination between events and non-events.  Several 
variables in the model were related to kidney function, indicating the critical nature of 
maintaining kidney function in preventing rehospitalization of heart failure patients. 
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5.6 Tables and Figures 
Table 11. – Demographic and Clinical Characteristics of Medicare Registry CRT-D Patients 
with and without 30-day Readmission 
 All 
Hospitalizations 
(n=607) 
Hospitalizations 
without 30-Day 
Readmission (n=500) 
Hospitalizations with 
30-Day Readmission 
(n=107) 
p-value* 
Age, mean ±SD, y 74.0±8.1 73.6±7.9 75.8±8.4 0.01 
Duration HF, mean ±SD, 
months 
30.5±29.7 29.2±29.0 36.5±32.2 0.02 
LVEF, mean ±SD, % 23.1±6.4 22.7±6.5 25.1±5.9 <0.01 
QRS duration, mean 
±SD, ms 
156.1±23.6 155.9±23.9 156.7±22.6 0.75 
SBP, mean ±SD, mm Hg 124.8±22.4 123.9±21.9 129.0±24.4 0.03 
DBP, mean ±SD, mm Hg 69.8±12.4 69.3±12.1 72.0±13.8 0.04 
Heart rate, mean ±SD, 
bpm 
70.9±13.7 71.3±14.0 68.9±11.8 0.07 
Sex, n(%)     
Female 28.0 27.0 33.7 0.23 
Male 72.0 73.0 67.3  
NYHA class, (%)     
I 1.7 1.2 3.7  
II 11.0 10.2 15.0  
III 72.5 72.0 74.8 0.01 
IV 14.8 16.6 6.5  
Ischemic CM, (%) 65.7 65.4 67.3 0.71 
Prior CABG, (%) 45.3 44.4 49.5 0.33 
BBB Morphology, (%)     
LBBB 71.7 70.2 78.5  
RBBB 9.9 9.8 10.3 0.10 
Other IVCD 18.5 20.0 11.2  
Atrial fibrillation, (%) 37.4 36.4 42.1 0.27 
Ventricular tachycardia, 
(%) 
18.3 18.4 17.8 0.88 
Sudden cardiac arrest, 
(%) 
2.0 2.0 1.9 0.93 
Diabetes mellitus, (%) 39.5 39.6 39.3 0.95 
Prior MI, (%) 48.1 46.4 56.1 0.07 
Chronic Kidney Disease, 
(%) 
45.3 42.0 60.8 <0.01 
End-Stage Renal 
Disease, (%) 
1.5 1.4 1.9 0.74 
Smoker Status, (%)     
Never 42.3 42.0 43.9  
Former 49.1 48.8 50.5 0.48 
Current 8.6 9.2 5.6  
Medications, (%)     
b-blocker 78.9 78.2 82.2 0.36 
ACEI or ARB 74.1 75.2 69.2 0.20 
Digoxin 40.5 42.6 30.8 0.02 
Diuretic 82.4 84.8 71.0 <0.01 
Amiodarone 11.7 12.4 8.4 0.20 
Warfarin 32.3 34.4 22.4 0.01 
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Figure 17. – Survival Free from HF-Hospitalization after Index HF Hospitalization by 
Number of Device-Measured Criteria Met on Day of Discharge 
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Table 12. – Hazard Ratios for Rates of 30-day Rehospitalization from Proportional Hazards 
Regression Modeling 
 Small, et al. Reported
57 Cohort, n=265 CareLink®- Medicare Cohort, n=607 
 Proportion Meeting 
Criterion, n(%) 
Hazard Ratios (95% 
CI) 
Proportion Meeting 
Criterion, n(%) 
Hazard Ratios (95%CI) 
Model Variables     
Reference 
Impedance - Daily 
Impedance > 8Ω  
7 (28%) 2.6	(1.2,5.6)	 38 (6.3%) 3.3	(2.0,5.8)	
AF Burden > 6h 
 
9 (20.5%) 1.7(0.6,5.1) 103 (17.0%) 0.9 (0.5,1.6) 
CRT Pacing < 
90% 
14 (28.6%) 3.1	(1.4,6.8)	 120 (19.8%) 1.2 (0.7,2.0) 
Night Heart Rate 
> 80 bpm 
12 (17.1%) 1.4 (0.7,2.7) 109 (18.0%) 1.1 (0.6,1.7) 
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Table 13. – Odds Ratios and Model Performance Metrics for Probability of 30-day Rehospitalization from Logistic Regression Modeling 
 Derivation Sample 
(n=418) 
Small, et al. Model, 
Validation Sample 
(n=189) 
Bootstrap Model, 
Validation Sample 
(n=189) 
Reduced Bootstrap Model, 
Validation Sample 
(n=189) 
Small, et al. 
Model, Full 
Cohort 
(n=607) 
Bootstrap Model, Full 
Cohort (n=607) 
Model Variables       
Reference Impedance - 
Daily Impedance > 8Ω  
4.37	(1.59,11.97)	 5.10	(1.64,15.86)	 5.34	(1.54,18.50)	 4.10	(1.41,11.96)	 4.06	
(2.03,8.11)	
4.27	(2.01,9.04)	
AF Burden > 6h 
 
1.10 (0.46,2.61) 1.24 (0.40,3.84) 0.84 (0.24,2.98) n/a 0.90 (0.47,1.72) 1.08 (0.54,2.16) 
CRT Pacing < 90% 1.43 (0.68,3.00) 0.63 (0.20,2.02) 0.65 (0.19,2.20) n/a 1.26 (0.71,2.25) 1.16 (0.63,2.15) 
Night Heart Rate > 80 bpm 1.55 (0.76,3.18) 1.21 (0.42,3.51) 1.27 (0.40,4.03) n/a 1.15 (0.66,1.98) 1.38 (0.76,2.50) 
Diuretic (Y/N) 0.30	(0.15,0.60)	 n/a 0.50 (0.18,1.43) n/a n/a 0.34	(0.20,0.60)	
Patient Sex (M/F) 3.82	(1.94,7.51)	 n/a 0.81 (0.30,2.17) n/a n/a 2.35	(1.37,4.01)	
Chronic Kidney Disease 
(Y/N) 
2.89	(1.59,5.26)	 n/a	 2.35	(1.02,5.42)	 2.27	(1.02,5.08)	 n/a 2.63	(1.63,4.24)	
NYHA Class 
I 
II 
III 
IV 
 
Ref. 
0.28 (0.04,1.81) 
0.24 (0.04,1.35) 
0.08 (0.01,0.54) 
 
 
n/a 
 
Ref. 
1.94 (0.11,34.98) 
1.39 (0.09,20.75) 
0.61 (0.03,12.78) 
 
 
n/a 
 
 
n/a 
 
Ref. 
0.52 (0.12, 2.30) 
0.47 (0.12,1.86) 
0.17 (0.04,0.79) 
Duration of HF at Index 
Hospitalization (years) 
1.12	(1.02,1.23)	 n/a	 1.27	(1.10,1.46)	 1.26	(1.10,1.44)	 n/a 1.16	(1.07,	1.24)	
Prior CABG Procedure 1.89	(1.03,3.48)	 n/a 1.61 (0.68,3.82) n/a n/a 1.64	(1.01,2.64)	
Discrimination       
AUC 0.78 (0.72,0.83) 0.61 (0.51,0.71) 0.76 (0.66,0.86) 0.73 (0.63,0.83) 0.59 (0.53,0.65) 0.77 (0.72,0.81) 
NRI n/a n/a 0.76 (0.41,1.10)† -0.39 (-0.74,-0.04)‡ n/a 0.69 (0.50,0.89)† 
Absolute IDI n/a n/a 0.129 (0.066,0.193)† -0.043 (-0.074,-0.0125)‡ n/a 0.097 (0.071,0.124)† 
Relative IDI n/a n/a 2.24† -0.23‡ n/a 2.78 
Calibration       
Hosmer-Lemeshow χ²  
(p-value) 
9.65 (0.29) 0.89 (0.93) 11.96 (0.15) 4.60 (0.80) 2.12 (0.98) 9.33 (0.32) 
*Equation from the bootstrap model in the derivation cohort is given by: 
 
†Comparing Bootstrap model to Small, et al., model.   
‡Comparing Reduced Bootstrap model to Bootstrap Model 
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Figure 18. – Hosmer-Lemeshow Calibration Plot of Small Model, Bootstrap Model, and 
Reduced Bootstrap Model 
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Figure 19. – Kaplan-Meier Plot of 30-Day HF-Rehospitalization Risk based on Tertile of 
Reduced Bootstrap Model-Predicted Risk 
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6 Summary	
The objectives in this dissertation were to examine associations between OptiVol® 
threshold crossings, bi-ventricular pacing percentage, heart rate variability, AF burden 
and overall patient mortality and HF-related hospitalization in a population of Medicare 
patients with over 6 years of follow-up.  Additionally, we sought to improve risk 
stratification models for HF-related rehospitalizations within 30-days, which are 
penalized by the Centers for Medicare and Medicaid Services. 
The first manuscript sought to determine associations between OptiVol® threshold 
crossings and overall patient mortality and HF-related hospitalizations.  Patients with 
>15.1% of days above OptiVol® threshold (highest quartile) had a more than 4-fold 
increase in all-cause mortality rate and a more than 3-fold increase in HF-related 
hospitalization rate compared with patients having <4.1% of days above threshold 
(lowest quartile).  In addition, a single OptiVol® crossing was associated with 
significantly increased rates of both mortality and HF-related hospitalization. 
In manuscript 2, we explored the complex relationship between bi-ventricular 
pacing, atrial fibrillation, and heart rate variability and overall patient mortality and HF-
related hospitalization in CRT-D patients.  Our main finding was that high levels of bi-
ventricular pacing and higher heart rate variability were associated with both lower rates 
of patient mortality as well as hospitalization.  However, we also found a complex 
interaction between AF burden and bi-V pacing, as well as a patient’s AVN ablation 
status, suggesting that a patient may lose the protective effect of high HRV after an 
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ablation, and that patients with AF also do not benefit from high levels of bi-ventricular 
pacing. This is complicated further by the fact that some device-measured information is 
either not available, or not meaningful in patients with persistent or permanent AF. 
Manuscript 3 sought to stratify risk of HF-related rehospitalization within 30 days 
of a prior HF-related hospitalization.  We examined the applicability of a prior risk-
stratification model to our cohort of CRT patients with Medicare coverage, and further 
examined whether baseline patient demographic and clinical characteristics would 
improve the prediction of 30-day rehospitalization risk.  We found variables associated 
with kidney function to be of key importance in predicting 30-day HF-rehospitalization, 
in addition to other covariates. 
In this thesis we have, for the first time, combined device-measured data via 
Medtronic’s CareLink® network with registry data for Medicare beneficiaries.  This 
unique linkage has allowed us to create a large cohort of CRT-D patients with a long 
follow-up period to examine three clinically important questions on the management of 
heart failure patients implanted with CRT devices:  1.) management of patients based on 
intrathoracic impedance findings, 2.) understanding and management of patients based on 
atrial fibrillation and AVN ablation status, and 3.)  identifying patients at high risk of 30-
day rehospitalization on the day of discharge through device-measured and baseline 
clinical variables.  We were restricted, however, to the use of Medicare administrative 
claims data, and only have clinical information at the time of device implant, with no 
further information on time-dependent clinical covariates. 
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 This thesis has provided insight into how device-measured data can be added to 
in-person clinical evaluation to better treat heart failure patients implanted with a CRT 
device.  We propose that specific intervention strategies be developed and evaluated 
based on the measures identified here for the future benefit of patients.   
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